EP0733059B1 - Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen - Google Patents

Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen Download PDF

Info

Publication number
EP0733059B1
EP0733059B1 EP95905337A EP95905337A EP0733059B1 EP 0733059 B1 EP0733059 B1 EP 0733059B1 EP 95905337 A EP95905337 A EP 95905337A EP 95905337 A EP95905337 A EP 95905337A EP 0733059 B1 EP0733059 B1 EP 0733059B1
Authority
EP
European Patent Office
Prior art keywords
duplex
region
strand
hybrid
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP95905337A
Other languages
English (en)
French (fr)
Other versions
EP0733059A1 (de
EP0733059A4 (de
Inventor
Eric B. Kmiec
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of EP0733059A1 publication Critical patent/EP0733059A1/de
Publication of EP0733059A4 publication Critical patent/EP0733059A4/de
Application granted granted Critical
Publication of EP0733059B1 publication Critical patent/EP0733059B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Definitions

  • the present invention concerns the field of molecular genetics. Particularly it concerns nucleic acid compounds and methods of their use to introduce specific genetic alterations into living cultured eukaryotic cells. More particularly it concerns substantially Watson-Crick paired, duplex nucleic acids wherein a portion of one strand of the duplex comprises a 2'-O or 2'-OMe ribose containing nucleotides and the remainder comprise deoxyribose nucleotides.
  • nucleic acids are heteropolymers, i.e., polymers of non-identical subunits, which are linked by oriented phosphodiester bonds or their derivatives, into polymers.
  • Duplex nucleic acids are nucleic acids wherein each base of a first strand of the duplex corresponds to a base of a second strand of the duplex according to the scheme in which uracil or thymine and adenine correspond and cytosine and guanine correspond. Anti-parallel duplex strands having these correspondences are said to be Watson-Crick paired.
  • Duplex nucleic acids can be of two major types, ribonucleic acids and deoxyribonucleic acids.
  • Each ribonucleotide has an equivalent deoxyribonucleotide, e.g., adenosine and deoxyadenosine, cytidine and deoxycytidine, guanosine and deoxyguanosine, uridine and thymidine.
  • a nucleic acid in which both ribonucleotides and deoxyribonucleotides are present in the same strand is termed a mixed or chimeric (hereinafter "chimeric") nucleic acid.
  • a duplex nucleic acid in which deoxyribonucleotides and ribonucleotides correspond with each other is termed a hybrid-duplex. When two strands form a region of duplex nucleic acid for less than all of their bases, the resultant molecule is termed a heteroduplex.
  • the two strands of a duplex nucleic acid are not covalently bonded but are associated only by Watson-Crick pairing.
  • the two strands of a duplex can be linked by an oligonucleotide to form a single polymer.
  • the linking oligonucleotide is not Watson-Crick paired.
  • the heteroduplex in which the first and second strands are portions of a single polymer is termed a "hairpin duplex" or a "stem and loop" structure. The former term will be used hereinafter.
  • chimerism is a property of a nucleic acid polymer and hybridism is a property of a duplex.
  • an mRNA and its template form a hybrid duplex though neither is chimeric, while, for example, the chimeric octanucleotides 5'd(TTTT)-r(CCCC)3' and 5'r(GGGG)-d(AAAA)3' will form a Watson-Crick duplex with each other but the resultant duplex is not a hybrid-duplex.
  • a duplex nucleic acid which is not a hybrid-duplex is termed hereinafter a "homo-duplex".
  • a homo-duplex nucleic acid refers only to a deoxynucleotide containing duplex.
  • RNA molecules that are either self-cleaving or cleave other RNAs.
  • ribozymes i.e., RNA molecules that are either self-cleaving or cleave other RNAs.
  • chimeric ribozymes are active and are more resistant to nuclease digestion than RNA ribozymes.
  • Chimeric ribozymes are self-complementary, i.e., the Watson-Crick paired strands are covalently linked.
  • the compounds synthesized during the studies of chimeric ribozymes differ from the above-noted hybrid-duplex molecules, that were synthesized used for structural studies, in that chimeric ribozymes do not contain stable hybrid-duplexes.
  • a chimeric ribozyme having DNA binding arms binds to its substrate and forms a hybrid duplex. Yang, J.H., et al., 1990, Biochemistry 29:11156-60.
  • a new polynucleic acid sequence i.e, a new gene
  • the targeted cell can be used in culture or it can be used to construct a transgenic animal.
  • WO 93/16177 to J.G. Seidman describes techniques for using homologous recombination to introduce DNA into a eukaryotic cell under the special circumstance that the DNA contains a selectable marker.
  • homologous recombination can be obtained in higher eukaryotic cells by introduction of very long (> 1 kb) nucleic acids, these techniques require the application of elaborate selection techniques because the rate of illegitimate recombination in higher eukaryotes greatly exceeds that of homologous recombination.
  • a relationship between the structure of the target DNA and the rate of homologous recombination in mammalian cells can be inferred by studies that show that regions of alternating purine and pyrimidine bases, i.e., [d(TG) 30 ⁇ d(AC) 30 ], display an enranced rate of recombination. These effects were demonstrated in studies of non-replicating plasmids in cultured mammalian cells. Wahls, W.P., et al., 1990, Mol. Cell. Biol. 10:785-93. These experiments were not extended to show recombination between an exogenous nucleic acid and the genome of the cell.
  • RecA a protein that promotes homologous recombination in the bacteria, E. coil , to promote homologous recornbination in eukaryotic cells.
  • U.S.Pat No. 4,950,599 to W. Bertling discloses a very low rate of site-directed mutation and no enhancement in the rate of homologous recombination by use of RecA in eukaryotic cells.
  • Patent publications WO 93/22443 to D. Zarling and E. Sena, and publication 94/04032 to D.C. Gruenert and K. Kunzelmann both purport to correct a genetic defect in a cultured cell line related to cystic fibrosis.
  • the present invention provides a mixed ribo-deoxyribonucleic acid having at most one 3' end and one 5' end, which nucleic acid further comprises:
  • Such a mixed ribo-deoxyribonucleic acid which further comprises two regions homologous with a target sequence and a heterologous region, disposed there between, encoding the alteration may be used to introduce a predetermined alteration in a target sequence of the genome of an cultured cell, which cell contains a nucleus, in a method which comprises maintaining said mixed ribo-deoxyribonucleic acid within the nucleus of the cultured cell, whereby the alteration is introduced in the target sequence.
  • a cultured cell having altered characteristics may be selected.
  • the present invention further provides a compound for introducing a predetermined alteration into a target gene, which compound is a mixed ribo-deoxyribonucleic acid having a first strand and a second strand, in which the first strand comprises
  • Such a mixed ribo-deoxyribonucleic acid may be used to introduce a predetermined alteration in a target sequence of the genome of a cultured cell other than a yeast or fungus, which cell contains a nucleus, in a method which comprises maintaining said mixed ribo-deoxyribonucleic acid within the nucleus of the cultured cell, whereby the alteration is introduced in the target sequence.
  • the present invention also provides a compound for introducing a predetermined alteration into a target gene, which compound is a mixed ribo-deoxyribonucleic acid having at most one 3' end and one 5' end, which nucleic acid further comprises:
  • That compound may be used to introduce a predetermined alteration in a target sequence of the genome of a cultured cell, which cell contains a nucleus, by maintaining said mixed ribo-deoxyribonucleic acid within the nucleus of the cultured cell, whereby the alteration is introduced in the target sequence.
  • the present invention concerns single Covalently linked duplex oligonucleotides that are homologous with a gene of interest having both deoxyribonucleotides and ribonucleotides.
  • a gene of interest having both deoxyribonucleotides and ribonucleotides.
  • mutator non-corresponding base pairs.
  • the normal, constitutive cellular processes of homologous recombinants cause the mutator nucleotides to be inserted into the targeted genomic site.
  • the duplex oligonucleotides of the invention (hereinafter "chimeric vectors”) can be used to alter specifically a gene of interest by introducing into the gene the heterologous base pairs.
  • the heterologous base pairs can be base pairs different from the gene of interest, or base pairs in addition to those present in the gene of interest (an insertion), or, lastly, the heterologous base pairs can be the absence of base-pairs found in the gene of interest (a deletion).
  • the present invention is based, in part, on the discovery that the inclusion of a region of between about 15 and 50 base pairs of hybrid-duplex nucleic acid in the vector causes a greatly increased rate of alteration of the gene of interest.
  • the heterologous base pairs can be present in the vectors of the invention as either a homo-or a hybrid-duplex.
  • the heterologous base pairs are greater than 50 base pairs in length it is preferred that they be present as a homo-duplex.
  • the vector can be introduced into the target cell by any method known to allow for the introduction of nucleic acids into eukaryotic cells. Without limitation as to theory, the chimeric vector is believed to be engaged by the recombination/repair mechanisms of the target cell and to direct the alteration of the target gene by gene conversion or by homologous recombination.
  • the present invention encompasses duplex nucleic acids that contain both deoxyribose and ribose containing bases. Thus they contain regions of both DNA and RNA and are termed therefore termed "chimeric vectors."
  • the 2'-O of the ribonucleotides of the chimeric vector can be methylated. Any phosphodiester can be substituted by a phosphorothiodiester or methyphosphonodiester.
  • the chimeric vectors of the invention are a single nucleic acid polymer. Accordingly, the chimeric vectors of the invention must contain at least one region of between at least 1 base and more usually 3 or 4 bases that are not Watson-Crick paired. These unpaired regions serve as linkers between the two strands of Watson-Crick paired bases. In contrast to other chimeric nucleotides that have been synthesized having regions of unpaired nucleotides chimeric vectors have no enzymatic activity i.e., they do not catalyze chemical reactions or themselves undergo chemical reaction in the absence of an biological energy source such as ATP.
  • the bases of the linkers in the preferred embodiment are deoxyribonucleotides.
  • a chimeric vector having two linkers can be constructed so that the 3' and 5' ends of the polymer are Watson-Crick paired to adjacent nucleotides of the complementary strand. They can then be readily ligated so that the chimeric vector forms a single continuous circular nucleic acid polymer.
  • bases are Watson-Crick paired.
  • bases are Watson-Crick paired or that they form a duplex nucleic acid. It is to be understood that under some conditions of low salt and/or elevated temperature the Watson-Crick base pairs may cease to be thermodynamically stable such that the duplex nucleic acid melts-out or denatures. It is also to be understood that a one or two base pair mismatch does not effect the operability of the invention.
  • the chimeric vectors of the present invention are intended for the purpose of specifically introducing alterations (a mutation) into a target gene.
  • the genetic site of the alteration is determined by selecting a portion of the chimeric vector to have the same sequence as (to be homologous with) the sequence of the target site, hereinafter termed a homologous region.
  • the area of differences between the sequence of the chimeric vector and the target gene are termed the heterologous region.
  • the chimeric vector is heterologous to the target gene, but is not a heteroduplex in this region of the vector.
  • each homologous region contains a portion of hybrid-duplex nucleic acid.
  • the portion of each hybrid-duplex can be at least 4 base pairs and preferably is 8 base pairs and more preferably about 20 to 30 base pairs.
  • the function of the chimeric vector is not effected by a dinucleotide base pair of homo-duplex within a region of hybrid duplex, placed to allow ligation of the 3' and 5' ends to each other.
  • the total length of the two homologous regions can be at least 20 base pairs and preferably is between 40 and 60 base pairs.
  • a region of homo-duplex nucleic acid can be disposed between the hybrid-duplex / homologous regions of the vector.
  • the interposed homo-duplex can contain the heterologous region.
  • the heterologous region is less than about 50 base pairs and preferably less than about 20 base pairs, the presence of a interposed homo-duplex region is optional.
  • the heterologous region exceeds about 20 base pairs, an interposed homo-duplex that contains the heterologous region is preferred.
  • the chimeric vectors of the invention can be synthesized by any method.
  • the chimeric vectors can most readily be synthesized by modification of the techniques used in the solid phase synthesis of DNA. Reviewed Caruthers, M.H., 1985, science 230:281-85; Itakura, K., et al., 1984, Ann.Rev.Biochem. 53:523-56.
  • Chimeric vectors having a homo-duplex region interposed between two hybrid-duplex regions can be constructed using semisynthetic techniques. Two synthetic chimeric polynucleic acids having a hairpin conformation are to be constructed. The free 5' and 3' ends of the two chimeric nucleic acids are constructed with an overlap staggered ends complementary to The overlap of two different restriction enzyme digest products. A homo-duplex region is provided having the complementary restriction enzyme digested ends.
  • the addition of a restriction enzyme sites to the ends of a cloned DNA fragment can be accomplished by techniques well understood by those skilled in the art, e.g., without limitation, PCR amplification with extended primers or the blunt end ligation of linkers containing the restriction site.
  • the two chimeric nucleotides and the homo-duplex region can be ligated by conventional enzymatic techniques.
  • the product, having chimeric oligonucleotides ligated at both ends can be separated from the incompletely reacted substrates by electrophoresis in 6% polyacrylamide gel in Tris Borate EDTA buffer under non-denaturing conditions.
  • the linear capped molecules are constrained and are electrophoresed more slowly under these conditions.
  • Chimeric vectors containing only naturally occurring nucleotides can be used for the present invention.
  • the chimeric vectors having regions of hybrid-duplex of about 20 ribonucleotides are found, in vitro, to be resistant to RNAse H. Resistance to enzymatic degradation can be obtained by the replacement of the ribonucleotides with 2'-O methylated ribonucleotides. Additionally or alternatively the phosphodiester bonds of the nucleic acid can be replaced by phosphorothiodiesters. Shimayama, T. et al., 1993, Nucleic Acids Research 21:2605. Arabinose containing nucleotides can also be used. As used herein the term nucleic acid is intended to encompass nucleic acids having these modifications.
  • the chimeric vectors of the present invention can be used to introduce a mutation in a specific location in the genome of a target cell.
  • the specific location of the target location is defined by its nucleic sequence hereinafter the target sequence.
  • a chimeric vector is constructed wherein the homology regions are identical to the target sequence, except for the presence of some regions of hybrid-duplex.
  • the change to be introduced is encoded by the heterologous region.
  • the change may be change in one or more bases of the sequence or the addition of one or more bases.
  • the invention may be practiced using one or two regions of hybrid duplex.
  • the heterologous region be contained within a homo-duplex region.
  • the practice of the invention requires that the chimeric vector be introduced into the nucleus of the target cell. Any method which causes such introduction can be used. Such methods include electroporation, DEAE-dextran, Ca PO 4 precipitation, liposome mediated fusion (LIPOFECTIN, Trade Mark), and direct injection. Electroporation is particularly suitable.
  • the chimeric vector can be used to construct transgenic animals.
  • the chimeric vector can be introduced into the pronucleus of a ovum by direct injection, according to the method described Brinster, R.L. et al., 1989, PROC.NATL.ACAD.SCI 86:7087; see also U.S. Patent No. 4,873,191 to T.E. Wagner and P.C. Hoppe.
  • the chimeric vector can be introduced into an embryonic stem cell, chimeric animals can be produced by aggregation of the embryonic stem cell with normal blastocyst cells, and transgenic animals can be recovered as offspring of the chimeric animals, according to the method of Capecchi, M.R., 1989, Science 244 : 1288.
  • the practice of the invention includes the use of a method to select the transformed cells from among the larger number of unmutated cells.
  • the transformation of the cells confers a growth advantage.
  • growth advantages include drug-resistance, alterations in growth regulation, and alterations in the capacity to utilize metabolites.
  • the method of selection can be negative selection whereby the transformed cells are rendered incapable of growth under the selecting conditions and the non-transformed cells are removed by exposure to conditions which selectively destroy proliferating cells.
  • the transformed cells may have an altered cell-surface antigenic phenotype that can be detected by immunofluorescence and selection can be performed by a Fluorescence Activated Cell Sorter.
  • the rate of transformation can be greater than 1 per 10,000 cells. The need for selection is thereby considerably reduced.
  • chimeric vector typically useful amounts of a chimeric vector are between 10 and 1000 ng of chimeric vector per million cultured cells to be transformed by electroporation.
  • Wild-type Ustilago has a functioning ura-3 gene whose product is part of the uracil biosynthetic pathway.
  • wild-type Ustilago is grown on 5'-fluororotic acid (5FOA)-media the cells die due to incorporation of the acid into the pathway. If the ura-3 gene is mutated so that ura-3 mRNA is not produced, the cells survive on the 5FOA media.
  • 5FOA 5'-fluororotic acid
  • the sequence of the endogenous ura-3 gene is known in the art.
  • base 358 of the sequence was changed from a thymidine to an adenine which mutation results in a dysfunctional protein.
  • a chimeric vector was synthesized as follows: Vector for mutation at base 358: (358 RNA Vector) 5' TGCCGATCGGCAAC TTTT GUUGCCGAUCGGCA AA T TT 3' (SEQ ID: 1)
  • the 358 vector adopts hairpin conformations. Underlined bases indicate ribonucleic acid residues. The bolded letter indicates the mutator (heterologous region). The italicized "T"'s indicate the unpaired bases.
  • a vector having the same sequence but containing no ribonucleic acids was also constructed for use as a control.
  • thymidine was substituted for uracil.
  • the control vector for mutation at base 358 (DNA 358 Vector) 5' TGCCGATCGGCAAC TTTT GTTGCCGA T CGGCAAA T TT 3' (SEQ ID: 2) also adopts a hairpin conformation. Again, the bolded residue is the mutator.
  • NIH 3T3 cells are human cells that have a benign (controlled) growth characteristics. Malignant (uncontrolled) growth characteristics are conferred by the single point mutation in the oncogene H - ras that replaces Gly 12 by Thr. Thus, the mutation G ⁇ T 12 leads to a readily selectable alteration in the growth characteristics. Taparowsky, E., et al., 1982, Nature 300:762; Sukumar S., et al., 1983, Nature 306:658.
  • Chimeric vectors were constructed to direct the G ⁇ T 12 mutation having the following sequence: The sequence is presented in the conventional single letter code with the additional features the RNA (underlined), unpaired bases are italicized , and the mutator base is bold . Note that after circularization the chimeric vector is divided into two substantially complementary strands by the two trithymidinyl sequences and that all the ribose containing nucleotides are present in only one of the two strands.
  • Two forms of the chimeric vector were synthesized using 2'-OMe ribose bases having respectively one ("R") and two ("R-D-R") regions of hybrid duplex flanking four deoxyribose residues.
  • the R-D-R form is shown above, SEQ ID: 3, the R form is identical except that bases 6-9 (“CGAC”) were deoxynucleotides. Note that the 5' and 3' termini are deoxynucleotides.
  • Control vectors were: 1) the same sequence lacking hybrid-duplex (data shown, “homo-duplex”); 2) the unpaired DNA (data shown “sDNA”) having the sequence 5'-GCCCACACCG A CGGCGCCACCAC-3' (SEQ ID 4); 3) the chimeric vector having no heterologous region and hence no mutator nucleotide (data not shown).
  • the experiment was conducted by transforming NIH 3T3 cells (1 x 10 6 cells) using an electroporation procedure. After electroporation, the cells were plated at a seeding density of 4 x 10 3 cells/cm 2 and allowed to grow for 14 days in culture. Transformants were visualized by staining foci-forming cells with crystal violet. As a positive control, the plasmid pT24 that encodes the T 12 form of H ras was employed. This control was used to determine the level of illegitimate recombination in the transfected NIH 3T3 cells. The experiment was repeated five times and a summary of the results are presented in tabular form below.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (50)

  1. Gemischte Ribo-Desoxyribonucleinsäure mit höchstens einem 3'-Ende und einem 5'-Ende, wobei die Nucleinsäure weiter
    a) wenigstens eine Region benachbarter, ungepaarter Basen, die so angeordnet sind, daß die ungepaarte Region die Nucleinsäure in einen ersten Strang und einen zweiten Strang teilt, die durch die Region der benachbarten, ungepaarten Basen verbunden sind, und
    b) wenigstens eine Region Watson-Crick-gepaarter Nucleinsäure mit einer Länge von wenigstens 15 Basenpaaren umfaßt, wobei die Basen des ersten Stranges mit Basen des zweiten Stranges korrespondieren, wobei
    c) der erste Strang eine Region von wenigstens drei benachbarten, ribosehaltigen Basen umfaßt, die innerhalb der Region der Watson-Crick-gepaarten Nucleinsäure einen Hybridduplex bilden.
  2. Nucleinsäure des Anspruchs 1, wobei der zweite Strang keine ribosehaltigen Basen enthält.
  3. Nucleinsäure des Anspruchs 1 oder Anspruchs 2, wobei die ribosehaltigen Basen 2'-O-methylierte Ribonucleotide sind und/oder die ein Phosphorthioat umfaßt, das einen Phosphodiester ersetzt und/oder die ein arabinosehaltiges Nucleotid umfaßt.
  4. Nucleinsäure eines der Ansprüche 1-3, die zwischen 15 und 50 Hybridduplex-Basenpaare umfaßt.
  5. Nucleinsäure wie in einem der Ansprüche 1-4 beansprucht, wobei das 5'- und 3'-Ende mit angrenzenden Basen eines komplementären Stranges in der Region der Watson-Crickgepaarten Nucleinsäure Watson-Crick-gepaart ist.
  6. Nucleinsäure wie in einem der Ansprüche 1-5 beansprucht, wobei das 5'- und 3'-Ende mit angrenzenden Basen des ersten Stranges Watson-Crick-gepaart ist.
  7. Nucleinsäure wie in einem der Ansprüche 1-6 beansprucht, die weiter eine zweite Region benachbarter, ungepaarter Basen umfaßt, die so angeordnet sind, daß die ungepaarte Region die Nucleinsäure in einen ersten Strang und einen zweiten Strang teilt, die durch die zweite Region benachbarter, ungepaarter Basen verbunden sind.
  8. Nucleinsäure wie in einem der Ansprüche 1-7 beansprucht, wobei der erste Strang zwei Regionen ribosehaltiger Basen umfaßt, die zwei Hybridduplexregionen bilden, wobei jede Hybridduplexregion eine Länge von wenigstens 8 Basenpaaren aufweist, und eine Zwischenregion von wenigstens 4 Basenpaaren eines Homoduplex umfaßt, die zwischen den Hybridduplexregionen angeordnet ist.
  9. Nucleinsäure wie in einem der Ansprüche 1-8 beansprucht, wobei die Zwischenregion aus einem Homoduplex aus zwischen 4 und 50 2'-Desoxyribosebasenpaaren besteht.
  10. Verfahren zum Einführen einer vorbestimmten Änderung in eine Zielsequenz des Genoms einer kultivierten Zelle, wobei die Zelle einen Kern enthält, das die Schritte des
    a) Bereitstellens der in einem der Ansprüche 1-9 beanspruchten gemischten Ribo-Desoxyribonucleinsäure, die weiter zwei mit einer Zielsequenz homologe Regionen und eine dazwischen angeordnete, die Änderung kodierende, heterologe Region umfaßt, und
    b) Erhaltens der gemischten Ribo-Desoxyribonucleinsäure in dem Kern der kultivierten Zelle umfaßt,
    wodurch die Änderung in die Zielsequenz eingeführt wird.
  11. verfahren von Anspruch 10, wobei der erste Strang der gemischten Ribo-Desoxyribonucleinsäure zwei Regionen benachbarter Nucleotide, die zwei Hybridduplexregionen bilden, wobei jede Hybridduplexregion eine Länge von wenig-stens 4 Basenpaaren aufweist, und eine zwischen den Hybridduplexregionen angeordnete Region aus wenigstens 1 Basenpaar eines Homoduplex umfaßt, der die heterologe Region umfaßt.
  12. verfahren wie in Anspruch 10 oder Anspruch 11 beansprucht, wobei die Zelle eine andere als die einer Hefe oder eines Pilzes ist.
  13. Verfahren wie in einem der Ansprüche 10-12 beansprucht, das weiter einen Schritt des Einführens der gemischten Ribo-Desoxyribonucleinsäure in den Kern durch die Verwendung eines Liposoms umfaßt.
  14. Verfahren wie in Anspruch 10 oder Anspruch 11 beansprucht, wobei der Kern ein Vorkern eines Eis ist und der Vektor aus der gemischten Ribo-Desoxyribonucleinsäure durch Injektion in den Vorkern eingeführt wird.
  15. verfahren wie in Anspruch 10 oder Anspruch 11 beansprucht, wobei der Kern ein Kern einer embryonalen Stammzelle ist und die Einführung durch Verwendung eines Liposoms oder durch Elektroporation erfolgt.
  16. verfahren zum Erhalten einer kultivierten Zelle mit geänderten Eigenschaften, das die Schritte des
    a) Bereitstellens der in einem der Ansprüche 1-9 bean-spruchten gemischten Ribo-Desoxyribonucleinsäure, die weiter zwei mit einer Zielsequenz homologe Regionen und eine dazwischen angeordnete, die Änderung kodierende, heterologe Region umfaßt,
    b) Erhaltens der gemischten Ribo-Desoxyribonucleinsäure in dem Kern der kultivierten Zelle, wodurch die gemischte Nucleinsäure und die Zielsequenz rekombinieren und die Zelle verändert wird, und
    c) Selektierens einer veränderten Zelle umfaßt.
  17. verfahren von Anspruch 16, wobei der erste Strang der gemischten Ribo-Desoxyribonucleinsäure zwei Regionen benachbarter Nucleotide, die zwei Hybridduplexregionen bilden, wobei jede Hybridduplexregion eine Länge von wenigstens 4 Basenpaaren aufweist, und eine dazwischen angeordnete Region aus wenigstens 1 Basenpaar eines zwischen den Hybridduplexregionen angeordneten Homoduplex aufweist, die die heterologe Region umfaßt.
  18. Verfahren wie in Anspruch 16 oder Anspruch 17 beansprucht, wobei die Zelle eine Säugerzelle ist.
  19. Verfahren wie in Anspruch 16 oder Anspruch 17 beansprucht, wobei die Zelle eine andere als die einer Hefe oder eines Pilzes ist.
  20. Verfahren zum Einführen einer vorbestimmten Änderung in ein Zielgen des Genoms einer kultivierten, eukaryotischen Zelle, die eine andere als die einer Hefe oder eines Pilzes ist, wobei die Zelle einen Kern enthält und das Verfahren die Schritte des
    a) Bereitstellens einer gemischten Ribo-Desoxyribonucleinsäure mit einem ersten Strang und einem zweiten Strang, wobei der erste Strang
    i. eine erste homologe Region und eine zweite homologe Region, die zusammen von einer Länge von 20 bis 60 Nucleotiden sind, die mit dem Zielgen homolog sind und mit dem zweiten Strang einen Duplex bilden, wobei jede homologe Region des ersten Stranges einen Abschnitt aus wenigstens 4 benachbarten Nucleotiden umfaßt, die mit Desoxynucleotiden des zweiten Stranges einen Hybridduples bilden, und
    ii. eine heterologe Region umfaßt, die zwischen der ersten und zweiten homologen Region angeordnet ist und von einer Länge von 1 bis 20 Nucleotiden ist, die mit dem Zielgen heterolog ist und die die vorbestimmte Änderung enthält, und
    b) Erhaltens der gemischten Ribo-Desoxyribonucleinsäure in dem Kern der kultivierten Zelle umfaßt,
    wodurch die Änderung in das Zielgen eingeführt wird.
  21. Verfahren des Anspruchs 20, wobei jedes einen Hybridduplex bildende Nucleotid des ersten Stranges eine ribosehaltige Base ist.
  22. Verfahren des Anspruchs 20, wobei ein einen Hybridduplex bildendes Nucleotid des ersten Stranges 2'-O-methyliert ist.
  23. Verfahren des Anspruchs 20, wobei jedes einen Hybridduplex bildende Nucleotid des ersten Stranges 2'-O-methyliert ist.
  24. Verfahren wie in einem der Ansprüche 20-23 beansprucht, wobei die heterologe Region aus Desoxyribonucleotiden besteht.
  25. Verfahren wie in einem der Ansprüche 20-24 beansprucht, wobei die Länge der heterologen Region ein Nucleotid beträgt.
  26. Verfahren wie in einem der Ansprüche 20-25 beansprucht, wobei die Änderung eine Insertion oder Deletion im Zielgen ist.
  27. Verbindung zum Einführen einer vorbestimmten Änderung in ein Zielgen, wobei die verbindung eine gemischte Ribo-Desoxyribonucleinsäure zum Einführen einer vorbestimmten Änderung in ein Zielgen ist, das einen ersten Strang und einen zweiten Strang aufweist, wobei der erste Strang
    a) eine erste homologe Region und eine zweite homologe Region, deren Länge zusammen 20 bis 60 Nucleotide beträgt, wobei die Regionen mit dem Zielgen homolog sind und mit dem zweiten Strang einen Duplex bilden, wobei jede homologe Region des ersten Strangs einen Abschnitt von wenigstens 4 benachbarten Nucleotiden umfaßt, die einen Hybridduplex mit Desoxynucleotiden des zweiten Stranges bilden, und
    b) eine heterologe Region umfaßt, die zwischen der ersten und zweiten homologen Region angeordnet ist und deren Länge 1 bis 20 blucleotide beträgt, die mit dem Zielgen heterolog ist und die die vorbestimmte Änderung enthält, wobei
    das Zielgen ein Gen einer eukaryotischen Zelle ist, die eine andere als die einer Hefe oder eines Pilzes ist.
  28. Gemischte Ribo-Desoxyribonucleinsäure des Anspruchs 27, wobei jedes einen Hybridduplex bildende Nucleotid des ersten Stranges eine ribosehaltige Base ist.
  29. Gemischte Ribo-Desoxyribonucleinsäure des Anspruchs 27, wobei ein einen Hybridduplex bildendes Nucleotid des ersten Stranges 2'-O-methyliert ist.
  30. Gemischte Ribo-Desoxyribonucleinsäure des Anspruchs 27, wobei jedes einen Hybridduplex bildende Nucleotid des ersten Stranges 2'-O-methyliert ist.
  31. Gemischte Ribo-Desoxyribonucleinsäure wie in einem der Ansprüche 27-30 beansprucht, wobei die heterologe Region aus Desoxyribonucleotiden besteht.
  32. Gemischte Ribo-Desoxyribonucleinsäure wie in einem der Ansprüche 27-31 beansprucht, wobei die Länge der heterologen Region ein Nucleotid beträgt.
  33. Gemischte Ribo-Desoxyribonucleinsäure wie in einem der Ansprüche 27-32 beansprucht, wobei die heterologe Region eine Insertion oder Deletion des Zielgens enthält.
  34. Verbindung zum Einführen einer vorbestimmten Änderung in ein zielgen, wobei die Verbindung eine gemischte Ribo-Desoxyribonucleinsäure mit höchstens einem 3'-Ende und einem 5'-Ende ist und die Nucleinsäure weiter
    a) wenigstens eine Region benachbarter, ungepaarter Basen, die so angeordnet sind, daß die ungepaarte Region die Nucleinsäure in einen ersten Strang und einen zweiten Strang trennt, die durch die Region aus benachbarten, ungepaarten Basen verbunden sind, und
    b) wenigstens eine Region Watson-Crick-gepaarter Nucleinsäure mit einer Länge von wenigstens 15 Basenpaaren umfaßt, wobei Basen des ersten Stranges Basen des zweiten Stranges entsprechen und wobei
    c) der zweite Strang eine Region von wenigstens neun Desoxyribonucleotiden umfaßt, die mit Nucleotiden des ersten Stranges einen Hybridduplex bilden, und
    d) die 5'- und 3'-Enden mit angrenzenden Basen eines komplementären Stranges Watson-Crick-gepaarter Nucleinsäure Watson-Crick-gepaart sind.
  35. Nucleinsäure des Anspruchs 34, wobei der erste Strang ein 2'-O-methyliertes Ribonucleotid umfaßt.
  36. Nucleinsäure von Anspruch 34, die wenigstens neun benachbarte Hybridduplex-Basenpaare umfaßt.
  37. Nucleinsäure wie in einem der Ansprüche 34-36 beansprucht, wobei der zweite Strang die 5'- und 3'-Enden umfaßt.
  38. Nucleinsäure wie in einem der Ansprüche 34-37 beansprucht, die wenigstens fünfzehn Hybridduplex-Basenpaare umfaßt.
  39. Nucleinsäure wie in einem der Ansprüche 34-38 beansprucht, wobei der erste Strang zwei Regionen benachbarter, die zwei Hybridduplexregionen bilden, wobei jede Hybridduplexregion eine Länge von wenigstens 4 Basenpaaren aufweist, und eine zwischen den Hybridduplexregionen angeordnete Zwischenregion aus wenigstens 1 Basenpaar eines Homoduplex umfaßt.
  40. Verfahren zum Einführen einer vorbestimmten Änderung in eine Zielsequenz des Genoms einer kultivierten Zelle, wobei die Zelle einen Kern enthält, das die Schritte des
    a) Bereitstellens der in einem der Ansprüche 33-38 beanspruchten, gemischten Ribo-Desoxyribonucleinsäure, die weiter zwei mit einer Zielsequenz homologe Regionen und eine dazwischen angeordnete, die Änderung kodierende heterologe Region umfaßt, und
    b) Erhaltens der gemischten Ribo-Desoxyribonucleinsäure in dem Kern der kultivierten Zelle umfaßt,
    wodurch die Änderung in die Zielsequenz eingeführt wird.
  41. Verfahren von Anspruch 40, wobei der erste Strang der gemischten Ribo-Desoxyribonucleinsäure zwei Regionen benachbarter Nucleotide, die zwei Hybridduplexregionen bilden, wobei jede Hybridduplexregion eine Länge von wenigstens 4 Basenpaaren aufweist, und eine zwischen den Hybridduplexregionen angeordnete Zwischenregion aus wenigstens 1 Homoduplex-Basenpaar umfaßt, die die heterologe Region umfaßt.
  42. Verfahren wie in Anspruch 40 oder Anspruch 41 beansprucht, wobei die Zelle eine andere als die einer Hefe oder eines Pilzes ist.
  43. Verfahren von Anspruch 42, das weiter einen Schritt des Einführens der gemischten Ribo-Desoxyribonucleinsäure in den Kern durch Verwendung eines Liposoms umfaßt.
  44. Verfahren wie in Anspruch 40 oder Anspruch 41 beansprucht, wobei der Kern ein Vorkern eines Eis ist und der Vektor aus der gemischten Ribo-Desoxyribonucleinsäure durch Injektion in den Vorkern eingeführt wird.
  45. Verfahren wie in Anspruch 40 oder Anspruch 41 beansprucht, wobei der Kern ein Kern einer embryonalen Stammzelle ist und die Einführung durch Verwendung eines Liposoms oder durch Elektroporation erfolgt.
  46. Verfahren des Erhaltens einer kultivierten Zellpopulation mit veränderten Eigenschaften, das die Schritte des
    a) Bereitstellens der gemischten Ribo-Desoxyribonucleinsäure des Anspruchs 34, die weiter zwei mit einer Zielsequenz homologe Regionen und eine dazwischen angeordnete, die Änderung kodierende heterologe Region umfaßt,
    b) Erhaltens der gemischten Ribo-Desoxyribonucleinsäure in dem Kern der kultivierten Zelle, wodurch die gemischte Nucleinsäure und die Zielsequenz rekombinieren und die Zelle verändert wird, und
    c) Selektierens einer veränderten Zelle umfaßt.
  47. Verfahren des Anspruchs 46, wobei der erste Strang der gemischten Ribo-Desoxyribonucleinsäure zwei Regionen benachbarter Nucleotide, die zwei Hybridduplexregionen bilden, wobei jede Hybridduplexregion eine Länge von wenigstens 4 Basenpaaren aufweist, und eine zwischen den Hybridduplexregionen angeordnete Zwischenregion aus wenigstens 1 Homoduplex-Basenpaar umfaßt, die die heterologe Region umfaßt.
  48. Verfahren wie in Anspruch 46 oder Anspruch 47 beansprucht, wobei die Zelle eine Säugerzelle ist.
  49. Verfahren wie in Anspruch 46 oder Anspruch 47 beansprucht, wobei die Zelle eine andere als die einer Hefe oder eines Pilzes ist.
  50. Gemischte Ribo-Desoxyribonucleinsäure wie in einem der Ansprüche 1 bis 9, 27 bis 33 oder 34 bis 39 definiert zur Verwendung bei der Herstellung eines transgenen Tieres.
EP95905337A 1993-12-09 1994-12-09 Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen Expired - Lifetime EP0733059B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US164303 1980-06-30
US16430393A 1993-12-09 1993-12-09
PCT/US1994/014181 WO1995015972A1 (en) 1993-12-09 1994-12-09 Compounds and methods for site-directed mutations in eukaryotic cells

Publications (3)

Publication Number Publication Date
EP0733059A1 EP0733059A1 (de) 1996-09-25
EP0733059A4 EP0733059A4 (de) 1997-05-21
EP0733059B1 true EP0733059B1 (de) 2000-09-13

Family

ID=22593886

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95905337A Expired - Lifetime EP0733059B1 (de) 1993-12-09 1994-12-09 Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen

Country Status (15)

Country Link
US (3) US5565350A (de)
EP (1) EP0733059B1 (de)
JP (1) JP3585238B2 (de)
KR (1) KR100386337B1 (de)
CN (2) CN1048254C (de)
AT (1) ATE196311T1 (de)
AU (1) AU691550B2 (de)
CA (1) CA2178729A1 (de)
DE (2) DE733059T1 (de)
DK (1) DK0733059T3 (de)
ES (1) ES2149962T3 (de)
GR (1) GR3034988T3 (de)
NZ (1) NZ278490A (de)
PT (1) PT733059E (de)
WO (1) WO1995015972A1 (de)

Families Citing this family (794)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268476A1 (en) * 1991-07-03 1998-04-30 Hyal Pharmaceutical Corporation Use of hyaluronan in gene therapy
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
US20020108136A1 (en) * 1997-03-21 2002-08-08 Sri Transgenic animals produced by homologous sequence targeting
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
EP0728139B1 (de) 1993-09-03 2003-08-13 Isis Pharmaceuticals, Inc. Aminoderivatisierte nukleoside und oligonukleoside
US6420549B1 (en) 1995-06-06 2002-07-16 Isis Pharmaceuticals, Inc. Oligonucleotide analogs having modified dimers
US5760012A (en) * 1996-05-01 1998-06-02 Thomas Jefferson University Methods and compounds for curing diseases caused by mutations
US5731181A (en) * 1996-06-17 1998-03-24 Thomas Jefferson University Chimeric mutational vectors having non-natural nucleotides
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) * 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20030044941A1 (en) 1996-06-06 2003-03-06 Crooke Stanley T. Human RNase III and compositions and uses thereof
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
DE69823324T2 (de) * 1997-03-03 2005-02-24 Applera Corp., Foster City Verbesserte chimäre oligonukleotidvektoren
US5948653A (en) * 1997-03-21 1999-09-07 Pati; Sushma Sequence alterations using homologous recombination
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
GB9711015D0 (en) * 1997-05-28 1997-07-23 Zeneca Ltd Improvements in or relating to organic compounds
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
NZ502929A (en) * 1997-08-05 2001-09-28 Kimeragen Inc The use of mixed duplex oligonucleotides to effect localized genetic changes in plants
WO1999025853A1 (en) 1997-11-18 1999-05-27 Pioneer Hi-Bred International, Inc. Targeted manipulation of herbicide-resistance genes in plants
DE69839742D1 (de) * 1997-11-18 2008-08-28 Pioneer Hi Bred Int Zusammensetzungen und Verfahren für die genetische Modifizierung von Pflanzen
US7102055B1 (en) 1997-11-18 2006-09-05 Pioneer Hi-Bred International, Inc. Compositions and methods for the targeted insertion of a nucleotide sequence of interest into the genome of a plant
EP0945507A1 (de) * 1998-03-27 1999-09-29 Boehringer Mannheim Gmbh Tumorspezifische Expressionskontrollregion und deren Verwendung
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US6010907A (en) * 1998-05-12 2000-01-04 Kimeragen, Inc. Eukaryotic use of non-chimeric mutational vectors
US6004804A (en) 1998-05-12 1999-12-21 Kimeragen, Inc. Non-chimeric mutational vectors
WO1999060012A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
AU753270B2 (en) 1998-05-21 2002-10-10 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
US6693185B2 (en) 1998-07-17 2004-02-17 Bayer Bioscience N.V. Methods and means to modulate programmed cell death in eukaryotic cells
DE19836098A1 (de) 1998-07-31 2000-02-03 Hoechst Schering Agrevo Gmbh Pflanzen, die eine modifizierte Stärke synthetisieren, Verfahren zur Herstellung der Pflanzen, ihre Verwendung sowie die modifizierte Stärke
IL142094A0 (en) 1998-09-29 2002-03-10 Gamida Cell Ltd Methods of controlling proliferation and differentiation of stem and progenitor cells
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
EP1131452B1 (de) 1998-11-09 2014-01-22 Bayer CropScience Aktiengesellschaft Nukleinsäuremoleküle kodierend für ein r1 protein aus reis und deren verwendung zur herstellung von veränderter stärke
US6438561B1 (en) * 1998-11-19 2002-08-20 Navigation Technologies Corp. Method and system for using real-time traffic broadcasts with navigation systems
US20030054390A1 (en) * 1999-01-19 2003-03-20 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6917882B2 (en) * 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
EP1151409A1 (de) * 1999-01-18 2001-11-07 Maxygen, Inc. Verfahren zum bevölkern von datenstrukturen für evolutionäre-simulationen
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US7024312B1 (en) * 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US20070065838A1 (en) 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
CA2320697C (en) * 1999-01-19 2014-11-18 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
US6127124A (en) * 1999-01-20 2000-10-03 Isis Pharmaceuticals, Inc. Fluorescence based nuclease assay
EP1165132B1 (de) * 1999-04-08 2011-10-19 Intercell USA, Inc. Trockenformulierung für transkutane immunisierung
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
AU4696700A (en) 1999-05-07 2000-11-21 E.I. Du Pont De Nemours And Company Auxin transport proteins
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US6271360B1 (en) 1999-08-27 2001-08-07 Valigen (Us), Inc. Single-stranded oligodeoxynucleotide mutational vectors
EP1218524A2 (de) * 1999-10-07 2002-07-03 Valigen Inc. Zusammensetzungen und verfahren zur genetischen veränderung von pflanzen
AR025996A1 (es) * 1999-10-07 2002-12-26 Valigen Us Inc Plantas no transgenicas resistentes a los herbicidas.
US7430477B2 (en) * 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US7332275B2 (en) 1999-10-13 2008-02-19 Sequenom, Inc. Methods for detecting methylated nucleotides
US7414170B2 (en) * 1999-11-19 2008-08-19 Kirin Beer Kabushiki Kaisha Transgenic bovines capable of human antibody production
US7074983B2 (en) * 1999-11-19 2006-07-11 Kirin Beer Kabushiki Kaisha Transgenic bovine comprising human immunoglobulin loci and producing human immunoglobulin
US7820878B2 (en) * 1999-11-19 2010-10-26 Kyowa Hakko Kirin Co., Ltd. Production of ungulates, preferably bovines that produce human immunoglobulins
WO2001035735A1 (en) * 1999-11-19 2001-05-25 Hematech, Llc Production of ungulates, preferably bovines that produce human immunoglobulins
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US6897020B2 (en) * 2000-03-20 2005-05-24 Newlink Genetics Inc. Methods and compositions for elucidating relative protein expression levels in cells
US20060134629A1 (en) * 2000-03-20 2006-06-22 Link Charles J Methods and compositions for elucidating protein expression profiles in cells
OA12240A (en) * 2000-03-27 2006-05-10 Univ Delaware Targeted chromosomal genomic alterations with modified single stranded oligonucleotides.
US6936467B2 (en) 2000-03-27 2005-08-30 University Of Delaware Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
AU2001263271A1 (en) * 2000-05-17 2001-11-26 University Of Delaware Plant gene targeting using oligonucleotides
US6656700B2 (en) * 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US6686188B2 (en) 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
WO2001094610A2 (en) * 2000-06-05 2001-12-13 Thomas Jefferson University Binary hybrid mutational vectors
US7468475B2 (en) 2000-06-16 2008-12-23 Schmuelling Thomas Method for modifying plant morphology, biochemistry and physiology
US6958214B2 (en) 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
WO2002010364A2 (en) * 2000-07-27 2002-02-07 University Of Delaware Methods for enhancing targeted gene alteration using oligonucleotides
US6875907B2 (en) 2000-09-13 2005-04-05 Pioneer Hi-Bred International, Inc. Antimicrobial peptides and methods of use
WO2002026967A2 (en) * 2000-09-25 2002-04-04 Thomas Jefferson University Targeted gene correction by single-stranded oligodeoxynucleotides
US20020123474A1 (en) * 2000-10-04 2002-09-05 Shannon Mark E. Human GTP-Rho binding protein2
US7560622B2 (en) 2000-10-06 2009-07-14 Pioneer Hi-Bred International, Inc. Methods and compositions relating to the generation of partially transgenic organisms
JP4420604B2 (ja) * 2000-12-22 2010-02-24 協和発酵キリン株式会社 再プログラムしたドナークロマチンまたはドナー細胞を用いて哺乳類をクローニングする方法
US20020142397A1 (en) * 2000-12-22 2002-10-03 Philippe Collas Methods for altering cell fate
US7491534B2 (en) 2000-12-22 2009-02-17 Kirin Holdings Kabushiki Kaisha Methods for altering cell fate to generate T-cells specific for an antigen of interest
WO2002059337A1 (en) * 2001-01-26 2002-08-01 Georgetown University School Of Medicine Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
AU2002303176A1 (en) * 2001-03-27 2002-10-15 University Of Delaware Genomics applications for modified oligonucleotides
AU2002303262A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene shinc-1 and diagnostic and therapeutic uses thereof
WO2002081639A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
US20030045830A1 (en) * 2001-04-17 2003-03-06 De Bizemont Therese Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis
US20040063922A1 (en) * 2001-04-17 2004-04-01 Conrad Charles A. Methods and compositions for catalytic DNA exchange in a sequence specific manner
US7053195B1 (en) * 2001-06-12 2006-05-30 Syngenta Participatious Ag Locked nucleic acid containing heteropolymers and related methods
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
KR100607612B1 (ko) 2001-06-20 2006-08-02 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
EP2221376B1 (de) 2001-06-21 2012-11-21 Isis Pharmaceuticals, Inc. Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
EP1925672A1 (de) 2001-06-22 2008-05-28 Syngeta Participations AG Auf abiotischen Stress ansprechende Polynukleotide und Polypeptide
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
CA2455424A1 (en) * 2001-08-07 2003-02-20 University Of Delaware Compositions and methods for the prevention and treatment of huntington's disease
AU2002322435A1 (en) * 2001-08-09 2003-02-24 Cibus Genetics Non-transgenic herbicide resistant plants
US7456335B2 (en) * 2001-09-03 2008-11-25 Basf Plant Science Gmbh Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants
EP1427856B1 (de) 2001-09-18 2011-05-11 Carnegie Institution Of Washington Fusionsproteine zur detektion von analyten
EP1487877B1 (de) 2001-09-18 2010-10-27 Genentech, Inc. Zusammensetzungen und verfahren für die diagnose von tumoren
EP1446503A2 (de) * 2001-09-27 2004-08-18 University Of Delaware Zusammensetzung und verfahren zur verbesserung der oligonukleotidgesteuerten veränderung von nukleinsäuresequenzen
WO2003027264A2 (en) * 2001-09-27 2003-04-03 University Of Delaware Coisogenic eukaryotic cell collections
US7468244B2 (en) * 2001-09-27 2008-12-23 University Of Delaware Polymorphism detection and separation
AU2002331897A1 (en) 2001-09-27 2003-04-07 Pioneer Hi-Bred International, Inc. Phytate polynucleotides and methods of use
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
NZ577565A (en) 2001-10-09 2010-10-29 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expressions
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
KR20070087247A (ko) 2002-01-02 2007-08-27 제넨테크, 인크. 종양의 진단 및 치료 방법 및 이를 위한 조성물
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (de) 2002-01-25 2006-06-07 Gamida Cell Ltd Verfahren zur expansion von stamm- und vorläuferzellen und damit erhaltene expandierte zellpopulationen
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
DE60337040D1 (de) 2002-02-01 2011-06-16 Life Technologies Corp Oligonukleotid-Zusammensetzungen mit verbesserter Wirksamkeit
US7135326B2 (en) * 2002-02-07 2006-11-14 E. I. Du Pont De Nemours And Company UDP-glucosyltransferases
EP1585386A4 (de) * 2002-02-20 2009-09-02 American Integrated Biolog Inc Rekombinante produktion im speichel
WO2003075856A2 (en) * 2002-03-07 2003-09-18 University Of Delaware Methods, compositions, and kits for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising a histone deacetylase inhibitor, lambda phage beta protein, or hydroxyurea
NZ535602A (en) 2002-04-08 2006-07-28 Pioneer Hi Bred Int Enhanced silk exsertion under stress in Zea mays plants
US7244565B2 (en) * 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US7138512B2 (en) * 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
EP1571968A4 (de) 2002-04-16 2007-10-17 Genentech Inc Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
US7432342B2 (en) 2002-05-03 2008-10-07 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof and related documents
CN1653174A (zh) 2002-05-08 2005-08-10 巴斯福植物科学有限公司 用于提高植物含油量的方法
US20030228317A1 (en) * 2002-05-22 2003-12-11 Prafulla Gokhale Gene BRCC-1 and diagnostic and therapeutic uses thereof
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US20030228558A1 (en) * 2002-06-11 2003-12-11 Bloom William Dennis Method of training brokers in a multi-level marketing business
WO2003106617A2 (en) * 2002-06-12 2003-12-24 Tel Aviv Medical Center Research Development Fund Oligonucleotides antibodies and kits including same for treating prostate cancer and determining predisposition thereto
WO2004026343A1 (ja) * 2002-09-20 2004-04-01 Sumitomo Phamaceuticals Co., Ltd. 部位特異的遺伝子変換促進剤および遺伝子疾患治療剤
WO2004031350A2 (en) 2002-09-26 2004-04-15 Amgen, Inc. Modulation of forkhead box o1a expression
AU2003282477A1 (en) * 2002-10-07 2004-05-04 Napro Bio Therapeutics, Inc. Methods and compositions for reducing screening in oligonucleotide-directed nucleic acid sequence alteration
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
WO2004044138A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
EP2957568B1 (de) 2002-11-05 2016-12-21 Ionis Pharmaceuticals, Inc. Zusammensetzungen mit alternierenden 2'-modifizierten nukleosiden zur verwendung bei der genmodulation
US9150605B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
KR20050093761A (ko) * 2002-11-08 2005-09-23 헤마테크, 엘엘씨 프리온 단백질 활성이 감소된 트랜스제닉 유제동물 및 그의용도
WO2004044181A2 (en) 2002-11-13 2004-05-27 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein b expression
DK1569695T3 (da) 2002-11-13 2013-08-05 Genzyme Corp Antisense-modulering af apolipoprotein-b-ekspression
US7754450B2 (en) 2002-11-15 2010-07-13 Morphotek, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
CN1726282B (zh) 2002-12-19 2012-09-26 拜尔作物科学股份公司 合成终粘度增加的淀粉的植物细胞及植物
US7468356B2 (en) 2003-02-11 2008-12-23 Antisense Therapeutics Ltd. Modulation of insulin like growth factor I receptor expression
EP1597371A2 (de) 2003-02-17 2005-11-23 Metanomics GmbH Herstellung von organismen mit schnellerem wachstum und/oder höherem ertrag
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
CA2868312A1 (en) 2003-03-31 2004-10-14 University Of Bristol Novel plant acyltransferases specific for long-chained, multiply unsaturated fatty acids
US20040205840A1 (en) * 2003-04-11 2004-10-14 Pioneer Hi-Bred International, Inc. Method for reducing gene expression
CN103131673A (zh) 2003-04-15 2013-06-05 巴斯福植物科学有限公司 编码非生物胁迫反应相关蛋白质的核酸序列，以及提高对环境胁迫耐性的植物和植物细胞
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
AU2004253455B2 (en) 2003-06-03 2011-03-03 Eli Lilly And Company Modulation of survivin expression
EP1644475A4 (de) * 2003-06-20 2009-06-03 Isis Pharmaceuticals Inc Doppelstrang-zusammensetzungen mit einem 3'-endo-modifizierten strang zur verwendung bei der genmodulation
EP2530157B1 (de) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von miRNAs
EP2169052B1 (de) 2003-08-01 2016-01-06 BASF Plant Science GmbH Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren in transgenen Organismen
CN1852985A (zh) 2003-08-01 2006-10-25 巴斯福植物科学有限公司 产生精细化学品的方法
ES2402417T3 (es) 2003-08-11 2013-05-03 Kweek-En Researchbedrijf Agrico B.V. Plantas resistentes a hongos y sus usos
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
CA2538252C (en) 2003-09-18 2014-02-25 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
CN100558893C (zh) 2003-09-18 2009-11-11 Isis药物公司 eIF4E表达的调节
EP1678194B1 (de) 2003-10-10 2013-06-26 Alchemia Oncology Pty Limited Modulation der synthese und des abbaus von hyaluronan bei der behandlung von krankheiten
EP2267154A1 (de) 2003-10-23 2010-12-29 Illumigen Biosciences, Inc. Oligoadenylate Synthetase
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
DK2295073T3 (da) 2003-11-17 2014-07-28 Genentech Inc Antistof mod cd22 til behandling af tumor af hæmatopoietisk oprindelse
US20050120397A1 (en) * 2003-11-24 2005-06-02 Hermann Steller Compounds and methods for regulation of spermatid differentiation
US20070118931A1 (en) 2003-12-17 2007-05-24 Cropdesign N.V. Plants having modified growth characteristics and method for making the same
WO2005062923A2 (en) * 2003-12-24 2005-07-14 Massachusetts Institute Of Technology Gene targets for enhanced carotenoid production
US7741070B2 (en) 2003-12-24 2010-06-22 Massachusetts Institute Of Technology Gene targets for enhanced carotenoid production
US7608699B2 (en) * 2003-12-29 2009-10-27 Rockefeller University Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof
JP2007520222A (ja) 2004-01-20 2007-07-26 アイシス ファーマシューティカルズ インコーポレイテッド グルココルチコイドレセプター発現の調節
US7468431B2 (en) 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
CA2799245C (en) 2004-02-25 2016-08-30 Pioneer Hi-Bred International, Inc. Novel bacillus thuringiensis crystal polypeptides, polynucleotides, and compositions thereof
MXPA06009572A (es) 2004-02-27 2007-05-23 Basf Plant Science Gmbh Metodo para la produccion de acidos grasos poliinsaturados en plantas transgenicas.
EP1720988B1 (de) 2004-02-27 2011-10-12 BASF Plant Science GmbH Verfahren zur herstellung von ungesättigten omega-3-fettsäuren in transgenen organismen
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8790919B2 (en) * 2004-03-15 2014-07-29 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of RNA by RNase H
WO2005094370A2 (en) 2004-03-29 2005-10-13 The General Hospital Corporation Oligonucleotide complex compositions and methods of use as gene alteration tools
EP2540734B1 (de) 2004-04-05 2016-03-30 Alnylam Pharmaceuticals, Inc. Prozess und Reagenzien für Oligonukleotidsynthese und -reinigung
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
AU2005237494B2 (en) 2004-04-22 2010-06-10 Kyowa Hakko Kirin Co., Ltd Transgenic animals and uses thereof
US20070072815A1 (en) * 2004-05-04 2007-03-29 Kmiec Eric B Methods and kits to increase the efficiency of oligonucleotide-directed nucleic acid sequence alteration
US7825293B2 (en) 2004-05-28 2010-11-02 Cropdesign N.V. Plants having improved growth characteristics and a method for making the same
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7193133B2 (en) 2004-06-09 2007-03-20 Michael Lassner Plastid transit peptides
EP1765857A2 (de) 2004-07-02 2007-03-28 Metanomics GmbH Verfahren zur herstellung feiner chemikalien
US8680062B2 (en) 2004-07-06 2014-03-25 Deliversir Ltd. System for delivering therapeutic agents into living cells and cells nuclei
US7928288B2 (en) 2004-07-12 2011-04-19 Cropdesign N.V. Plants having improved growth characteristics and method for making the same
ES2430827T3 (es) 2004-07-31 2013-11-21 Metanomics Gmbh Preparación de organismos con crecimiento más rápido y/o rendimiento más alto
US20060035858A1 (en) 2004-08-10 2006-02-16 Geary Richard S Methods for modulating lipoprotein and cholesterol levels in humans
AU2005273864B2 (en) 2004-08-16 2010-09-30 Cropdesign N.V. Plants having improved growth characteristics and method for making the same
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
EP1799812A4 (de) 2004-09-16 2009-09-09 Gamida Cell Ltd Verfahren zur ex-vivo-expansion von progenitor- und stammzellen durch gemeinsame kultivierung mit mesenchymzellen
JP2008513507A (ja) 2004-09-17 2008-05-01 アイシス ファーマシューティカルズ インコーポレイティッド 増強されたアンチセンスオリゴヌクレオチド
CA2579800A1 (en) 2004-09-24 2006-03-30 Basf Plant Science Gmbh Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress
JP2008516991A (ja) 2004-10-20 2008-05-22 アンチセンス セラピューティクス リミテッド インテグリンα４発現のアンチセンス調節
CN101090972A (zh) 2004-10-29 2007-12-19 克罗普迪塞恩股份有限公司 具有改良生长特性的植物及其制备方法
CA2585798A1 (en) 2004-12-17 2006-06-17 Metanomics Gmbh Process for the control of production of fine chemicals
AR051866A1 (es) 2004-12-24 2007-02-14 Cropdesign Nv Plantas con aumento del rendimiento y metodo de prepracion
AU2004326206B2 (en) 2004-12-28 2011-03-17 Pioneer Hi-Bred International, Inc. Improved grain quality through altered expression of seed proteins
JP2008528014A (ja) 2005-01-27 2008-07-31 クロップデザイン エヌ．ブイ． 収量が増加した植物および該植物を作製する方法
ATE530656T1 (de) 2005-02-23 2011-11-15 Univ North Carolina State Veränderung des alkaloidgehaltes in tabak durch modifikation spezifischer cytochrome p450 gene.
WO2006092449A2 (en) 2005-03-02 2006-09-08 Metanomics Gmbh Process for the production of fine chemicals
EP2573188A2 (de) 2005-03-02 2013-03-27 Metanomics GmbH Verfahren zur Herstellung von Feinchemikalien
AU2006222012B2 (en) 2005-03-08 2011-03-31 Basf Plant Science Gmbh Expression enhancing intron sequences
KR20070110077A (ko) 2005-03-10 2007-11-15 제넨테크, 인크. 혈관 완전성을 조정하기 위한 방법 및 조성물
DE102005013779A1 (de) 2005-03-22 2006-09-28 Basf Plant Science Gmbh Verfahren zur Herstellung von mehrfach ungesättigten C20- und C22-Fettsäuren mit mindestens vier Doppelbindungen in transgenen Pflanzen
EP1707632A1 (de) 2005-04-01 2006-10-04 Bayer CropScience GmbH Phosphorylierte waxy-Kartoffelstärke
WO2006113666A2 (en) 2005-04-19 2006-10-26 Massachusetts Institute Of Technology Amphiphilic polymers and methods of use thereof
CN101203611B (zh) 2005-04-19 2013-08-14 巴斯福植物科学有限公司 控制基因表达的改良方法
US20070011752A1 (en) * 2005-05-06 2007-01-11 American Integrated Biologics, Inc. Production of human proteins in transgenic animal saliva
EP2261361A3 (de) 2005-05-25 2011-04-20 Pioneer Hi-Bred International Inc. Verfahren zur besserung der architektur und des ertrags von getreide pflanzen
JP5329949B2 (ja) 2005-05-31 2013-10-30 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ 遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
EP1896594B1 (de) 2005-06-23 2011-01-12 BASF Plant Science GmbH Verbesserte verfahren zur herstellung stabil transformierter und fruchtbarer buntmais-pflanzen
BRPI0612710A2 (pt) 2005-07-06 2012-10-02 Cropdesign Nv método para aumentar o rendimento de plantas com relação às plantas de controle, e para produzir uma planta transgênica tendo rendimento aumentado, planta, construção, partes coletáveis de uma planta, produtos, e, uso de um ácido nucleico / gene de tipo ste20 ou variante do mesmo, ou uso de um polipeptìdeo de tipo ste20 ou seu homólogo
DE102005038036A1 (de) 2005-08-09 2007-02-15 Basf Plant Science Gmbh Verfahren zur Herstellung von Arachidonsäure und/oder Eicosapentaensäure in transgenen Nutzpflanzen
WO2007020198A2 (en) 2005-08-12 2007-02-22 Basf Plant Science Gmbh Nucleic acid sequences encoding proteins associated with abiotic stress response and plant cells and plants with increased tolerance to environmental stress
US7842856B2 (en) 2005-08-25 2010-11-30 The Board Of Trustees Of The University Of Illinois Herbicide resistance gene, compositions and methods
US8071840B2 (en) 2005-09-15 2011-12-06 Cropdesign N.V. Plants having increase yield and method for making the same
AU2006298844B2 (en) 2005-09-20 2012-01-12 Basf Plant Science Gmbh Methods for controlling gene expression using ta-siRAN
GB2431158A (en) 2005-10-13 2007-04-18 Rothamsted Res Ltd Process for the production of arachidonic and/or eicosapentaenoic acid
EP2333089A1 (de) 2005-11-07 2011-06-15 CropDesign N.V. Klasse I Homeodomain leucine zipper (HDZip) hox5 Polypetid-exprimierende Pflanzen mit verbesserten Wachstumseigenschasften und Methode zu deren Erzeugung
US8853492B2 (en) 2005-11-07 2014-10-07 Cropdesign N.V. Plants having improved growth characteristics and a method for making the same
AR056790A1 (es) 2005-11-08 2007-10-24 Cropdesign Nv Plantas con caracteristicas de crecimiento aumentado y un metodo para obtenerlas
CA2628505A1 (en) * 2005-11-08 2007-05-18 Basf Plant Science Gmbh Use of armadillo repeat (arm1) polynucleotides for obtaining resistance to pathogens in plants
CN102174085A (zh) 2005-11-10 2011-09-07 先锋高级育种国际公司 Dof(具有一指的dna结合)序列和使用方法
US20070199096A1 (en) 2005-11-14 2007-08-23 E.I. Du Pont De Nemours And Company Compositions and Methods for Altering Alpha- and Beta-Tocotrienol Content
EP1966377A2 (de) 2005-11-21 2008-09-10 Isis Pharmaceuticals, Inc. Modulation der eif4e-bp2-expression
US7723574B2 (en) 2005-11-24 2010-05-25 Basf Plant Science Gmbh Process for the production of Δ5-unsaturated fatty acids in transgenic organisms
MX2008006663A (es) * 2005-11-24 2008-09-22 Basf Se Proteinas efectoras de union a queratina quimericas.
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
EP2166086A3 (de) 2005-12-01 2010-10-20 CropDesign N.V. Pflanzen mit verbesserten Wachstumseigenschaften und Verfahren zu ihrer Herstellung
US20090105341A1 (en) 2005-12-24 2009-04-23 Teagasc Dairy Products Research Centre Process for the production of trans-10, cis 12 octadecadienoic acid
JP5713377B2 (ja) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
US7592505B2 (en) 2005-12-30 2009-09-22 Pioneer Hi-Bred International, Inc. UDP-xylose synthases (UXS) polynucleotides, polypeptides, and uses thereof
NZ704098A (en) 2006-01-12 2015-02-27 Incima Ipco B V Epsps mutants
EP1979484B1 (de) 2006-01-12 2014-03-19 BASF Plant Science GmbH Verwendung von stomatin (stm1)-polynukleotiden zur erreichung einer resistenz gegen krankheitserreger von pflanzen
DK2161038T3 (da) 2006-01-26 2014-03-03 Isis Pharmaceuticals Inc Sammensætninger og deres anvendelser rettet mod Huntington
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
EP2388328A1 (de) 2006-01-27 2011-11-23 Isis Pharmaceuticals, Inc. Oligomerverbindungen und Zusammensetzungen zur Verwendung bei der Modulation von microRNAs
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
BRPI0707413A2 (pt) 2006-02-09 2011-05-03 Pioneer Hi Bred Int genes para aprimoramento da eficiência de utilização do nitrogênio em culturas
GB0603160D0 (en) 2006-02-16 2006-03-29 Rothamsted Res Ltd Nucleic acid
US20090172834A1 (en) 2006-03-24 2009-07-02 Basf Plant Science Gmbh Proteins Associated With Abiotic Stress Response And Homologs
ES2553384T3 (es) 2006-03-31 2015-12-09 Basf Plant Science Gmbh Plantas que tienen rasgos potenciados relacionados con el rendimiento y un procedimiento de producción de las mismas
EP2090662A3 (de) 2006-04-05 2012-10-31 Metanomics GmbH Verfahren zur Herstellung einer feinen Chemikalie
BRPI0710455A2 (pt) 2006-04-19 2011-08-16 Pioneer Hi Bred Int polipeptìdeo isolado, polinucleotìdeo isolado e métodos para aumentar o nìvel de um polipeptìdeo em uma planta, para modular o nìvel de um polipeptìdeo em uma planta e para modificar o crescimento de uma planta
WO2007143317A2 (en) 2006-05-05 2007-12-13 Isis Pharmaceuticals, Inc Compounds and methods for modulating expression of crp
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
JP5441688B2 (ja) 2006-05-11 2014-03-12 アイシス ファーマシューティカルズ， インコーポレーテッド ５’修飾二環式核酸類似体
EP2377937A1 (de) 2006-05-30 2011-10-19 CropDesign N.V. Pflanzen mit reduzieter Expression von einem CLE-artigen-Gen mit verbesserten Ertragseigenschaften und Verfahren zu ihrer Herstellung
CN106222179A (zh) 2006-05-31 2016-12-14 梅坦诺米克斯有限公司 使用铵转运蛋白或者葡萄糖‑6‑磷酸脱氢酶或者法呢基磷酸合成酶（fpp）的氮代谢操作
CN103215288A (zh) 2006-06-08 2013-07-24 巴斯福植物科学有限公司 具有改良生长特性的植物及其制备方法
EP2599870A3 (de) 2006-06-15 2013-09-11 CropDesign N.V. Pflanzen mit verbesserten Ertragseigenschaften und Verfahren zu ihrer Herstellung
WO2007144190A2 (en) 2006-06-15 2007-12-21 Cropdesign N.V. Plants with modulated expression of nac transcription factors having enhanced yield-related traits and a method for making the same
AU2007363151B2 (en) * 2006-06-28 2014-12-11 Cibus Europe B.V. Alkylester fatty acid blends and uses therefor
RU2483057C2 (ru) 2006-06-28 2013-05-27 Ньюселис Инк. Смеси жирных кислот и их применение
US8198253B2 (en) 2006-07-19 2012-06-12 Isis Pharmaceuticals, Inc. Compositions and their uses directed to HBXIP
EP2054516B1 (de) 2006-08-02 2014-01-08 CropDesign N.V. Pflanzen mit verbesserten eigenschaften sowie verfahren zur herstellung davon
ES2558133T3 (es) 2006-08-02 2016-02-02 Cropdesign N.V. Plantas transformadas con el polipéptido SYT que tienen el rendimiento aumentado en estrés abiótico y procedimiento de producción de las mismas
DK2059600T3 (da) 2006-08-30 2014-07-07 Basf Plant Science Gmbh Fremgangsmåde til forøgelse af patogenresistensen i transgene planter
US9155749B2 (en) 2006-09-14 2015-10-13 Medgenics Medical Israel Ltd. Long lasting drug formulations
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
EP2182056B1 (de) 2006-10-06 2015-12-23 BASF Plant Science GmbH Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren in transgenen nicht-humanen Organismen
EP2487245A3 (de) 2006-10-12 2012-10-24 BASF Plant Science GmbH Verfahren zur Erhöhung der Pathogenresistenz in transgenen Pflanzen
BRPI0719824A2 (pt) 2006-10-13 2014-06-03 Basf Plant Science Gmbh Método para produzir uma célula vegetal transgênica, uma planta ou uma parte da mesma, célula hospedeira transformada, célula vegetal transgênica, uma planta ou uma parte da mesma, semente, tecido vegetal, material de propagação, material colhido ou uma planta, e, uso de uma molécula de ácido nucleico.
ES2389689T3 (es) 2006-10-24 2012-10-30 Basf Plant Science Gmbh Método para incrementar la resistencia frente a hongos biotrópicos en vegetales
MX2009005160A (es) 2006-11-16 2009-05-28 Basf Plant Science Gmbh Plantas que tienen rasgos relacionados con rendimiento mejorados y un metodo para hacer las mismas usando secuencias de consenso de la familia de proteina y abby.
CA2664987A1 (en) 2006-11-24 2008-05-29 Cropdesign N.V. Transgenic plants comprising as transgene a class i tcp or clavata 1 (clv1) or cah3 polypeptide having increased seed yield and a method for making the same
EP2069504B1 (de) 2006-12-15 2015-06-03 CropDesign N.V. Pflanzen mit verbesserten eigenschaften bezüglich des samenertrags und verfahren zu ihrer herstellung
CN102676575B (zh) 2006-12-21 2015-09-30 巴斯福植物科学有限公司 具有增强的产量相关性状的植物和用于产生该植物的方法
EP1935428A1 (de) * 2006-12-22 2008-06-25 Antisense Pharma GmbH Oligonukleotid-Polymer Konjugate
US7872170B2 (en) 2006-12-28 2011-01-18 Pioneer Hi-Bred International, Inc. Genetic markers for orobanche resistance in sunflower
DK2155228T3 (da) 2007-01-10 2014-07-07 Purdue Research Foundation Polypeptidinhibitorer af HSP27-kinase og anvendelser herfor
WO2008087141A2 (en) 2007-01-15 2008-07-24 Basf Plant Science Gmbh Use of subtilisin (rnr9) polynucleotides for achieving a pathogen resistance in plants
WO2008092910A1 (en) 2007-01-30 2008-08-07 Cropdesign N.V. Plants having enhanced yield-related traits and a method for making the same
WO2008092935A2 (en) 2007-01-31 2008-08-07 Basf Plant Science Gmbh Plants having enhanced yield-related traits and/or increased abiotic stress resistance, and a method for making the same
CA2691066C (en) 2007-02-09 2018-07-31 Northwestern University Particles for detecting intracellular targets
ES2574981T3 (es) 2007-02-28 2016-06-23 Cropdesign N.V. Plantas que tienen rasgos potenciados relacionados con el rendimiento y procedimiento de producción de las mismas
US8153863B2 (en) * 2007-03-23 2012-04-10 New York University Transgenic plants expressing GLK1 and CCA1 having increased nitrogen assimilation capacity
US20100287641A1 (en) 2007-04-04 2010-11-11 Basf Plant Science Gmbh Ahas mutants
US9156865B2 (en) 2007-04-23 2015-10-13 Deliversir Ltd System for delivering therapeutic agents into living cells and cells nuclei
US9556210B2 (en) 2007-04-23 2017-01-31 Sabag-Rfa Ltd. System for delivering therapeutic agents into living cells and cells nuclei
WO2008129548A2 (en) * 2007-04-23 2008-10-30 Segev Laboratories Limited A system for delivering therapeutic agents into living cells and cells nuclei
WO2008137108A2 (en) 2007-05-03 2008-11-13 Basf Plant Science Gmbh Plants having enhanced yield-related traits and a method for making the same
EP2074220A2 (de) 2007-05-22 2009-07-01 BASF Plant Science GmbH Pflanzenzellen mit erhöhter toleranz und/oder resistenz gegenüber umweltstress und erhöhter biomasseproduktion
US20100251416A1 (en) 2007-05-22 2010-09-30 Basf Plant Science Gmbh Plants with increased tolerance and/or resistance to environmental stress and increased biomass production
WO2008142163A2 (en) 2007-05-23 2008-11-27 Cropdesign N.V. Plants having enhanced yield-related traits and a method for making the same
AU2008257572A1 (en) 2007-05-25 2008-12-04 Cropdesign N.V. Yield enhancement in plants by modulation of maize Alfins
DK2160464T3 (da) 2007-05-30 2014-08-04 Univ Northwestern Nukleinsyrefunktionaliserede nanopartikler til terapeutiske anvendelser
ES2388590T3 (es) 2007-05-30 2012-10-16 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos con puente aminometileno N-sustituido.
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
CN102027120A (zh) 2007-06-29 2011-04-20 巴斯夫植物科学有限公司 具有增强的产量相关性状的植物和用于制备该植物的方法
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
ES2440265T3 (es) 2007-07-20 2014-01-28 Basf Plant Science Gmbh Plantas que tienen un aumento de características relacionadas con el rendimiento y un método para elaboración de las mismas
MX2010001128A (es) 2007-07-31 2010-03-09 Basf Plant Science Gmbh Plantas que contienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas.
AR067748A1 (es) 2007-07-31 2009-10-21 Basf Plant Science Gmbh Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas
JP5703466B2 (ja) * 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
WO2009023855A2 (en) 2007-08-15 2009-02-19 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
MX2010002753A (es) 2007-09-14 2010-03-30 Basf Plant Science Gmbh Plantas que tienen rasgos aumentados relacionados con el rendimiento y un metodo para obtenerlas.
CN103695459A (zh) 2007-09-18 2014-04-02 巴斯夫植物科学有限公司 产量提高的植物
WO2009039442A1 (en) 2007-09-21 2009-03-26 California Institute Of Technology Nfia in glial fate determination, glioma therapy and astrocytoma treatment
EP2594646A3 (de) 2007-09-21 2013-11-06 BASF Plant Science GmbH Pflanze mit erhöhtem Ertrag
US20100199382A1 (en) 2007-09-21 2010-08-05 Basf Plant Science Gmbh Plants Having Increased Yield-Related Traits And A Method For Making The Same
DK2700721T3 (en) 2007-10-05 2019-04-01 Cibus Europe Bv MUTERATED ACETOH HYDROXY ACID SYNTHASIC GENES IN BRASSICA
US20100280098A1 (en) * 2007-10-05 2010-11-04 Juliano Rudolph L Receptor targeted oligonucleotides
US20110071047A1 (en) * 2007-10-27 2011-03-24 O.D. 260 Inc. Promoter detection and analysis
US20090111099A1 (en) * 2007-10-27 2009-04-30 Yongsheng Ma Promoter Detection and Analysis
AU2008320931B2 (en) 2007-10-29 2014-09-25 Basf Plant Science Gmbh Plants having enhanced yield-related traits and a method for making the same
CN101939431B (zh) 2007-11-12 2015-01-28 北卡罗来纳州立大学 通过修饰特定细胞色素p450基因改变烟草生物碱含量
US8637478B2 (en) * 2007-11-13 2014-01-28 Isis Pharmaceuticals, Inc. Compounds and methods for modulating protein expression
US8916531B2 (en) 2007-11-20 2014-12-23 Isis Pharmaceuticals, Inc. Modulation of CD40 expression
CN103952415A (zh) 2007-11-20 2014-07-30 先锋国际良种公司 用于改善植物应激耐性的玉米乙烯信号转导基因及其调节
US8546556B2 (en) * 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
ES2423209T3 (es) 2007-11-22 2013-09-18 Cropdesign N.V. Plantas que tienen un aumento de características relacionadas con el rendimiento y un método para elaboración de las mismas
EP2581385A1 (de) 2007-11-26 2013-04-17 BASF Plant Science GmbH Pflanzen mit verbesserten Ertragseigenschaften und Verfahren zu ihrer Herstellung
AU2008337398B2 (en) * 2007-12-19 2014-04-03 Basf Plant Science Gmbh Plants with increased yield and/or increased tolerance to environmental stress (IY-BM)
US8575421B2 (en) 2007-12-20 2013-11-05 Basf Plant Science Gmbh Plants having enhanced yield-related traits and a method for making the same
AU2008340002A1 (en) * 2007-12-21 2009-07-02 Basf Plant Science Gmbh Plants with increased yield (KO NUE)
DE112009000148T5 (de) 2008-01-25 2011-04-14 Basf Plant Science Gmbh Pflanzen mit verbesserten Ertragsmerkmalen und Verfahren zu ihrer Herstellung
CN101978064A (zh) 2008-01-31 2011-02-16 北京生命科学研究所 具有改变的生长和/或发育的植物及其生产方法
WO2009100320A2 (en) 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
DE112009000313T5 (de) 2008-02-27 2011-04-28 Basf Plant Science Gmbh Pflanzen mit erhöhtem Ertrag
EP2282744B1 (de) 2008-03-21 2018-01-17 Ionis Pharmaceuticals, Inc. Oligomere verbindungen mit trizyklischen nukleosiden und anwendungsverfahren dafür
EP2285819B1 (de) 2008-04-04 2013-10-16 Isis Pharmaceuticals, Inc. Oligomere verbindungen, die neutral gebundene, terminal bicyclische nukleoside enthalten
EP2268820A1 (de) 2008-04-16 2011-01-05 BASF Plant Science GmbH Pflanzen mit verbesserten ertragseigenschaften und verfahren zu ihrer herstellung
EP2274431A1 (de) 2008-05-05 2011-01-19 BASF Plant Science GmbH Pflanzen mit verbesserten ertragseigenschaften und verfahren zu ihrer herstellung
UA108343C2 (uk) * 2008-05-23 2015-04-27 Нуцеліс Інк. Спосіб одержання сквалену за допомогою дріжджів
EP2711424A3 (de) 2008-06-20 2014-05-14 BASF Plant Science GmbH Pflanzen mit verbesserten Ertragseigenschaften und Verfahren zu ihrer Herstellung
CN102131934B (zh) 2008-06-26 2014-03-12 巴斯夫植物科学有限公司 具有增强的产量相关性状的植物及其制备方法
EP2297192A1 (de) 2008-07-04 2011-03-23 BASF Plant Science GmbH Pflanzen mit verbesserten ertragseigenschaften und verfahren zu ihrer herstellung mittels überexpression eines für ein tfl1-like-protein codierenden polynukleotids
EP2657341A3 (de) 2008-07-17 2014-01-22 BASF Plant Science GmbH Pflanzen mit verbesserten Ertragseigenschaften und Verfahren zu ihrer Herstellung
US9074006B2 (en) 2008-07-31 2015-07-07 Basf Plant Science Gmbh Use of HUB1 polynucleotides for improving growth characteristics in plants
CA2735710A1 (en) 2008-08-04 2010-02-11 Glen N. Barber Sting (stimulator of interferon genes), a regulator of innate immune responses
CA2734347A1 (en) 2008-08-19 2010-02-25 Basf Plant Science Gmbh Plants with increased yield by increasing or generating one or more activities in a plant or a part thereof
CN104531751A (zh) 2008-08-20 2015-04-22 巴斯夫植物科学有限公司 具有增强的产量相关性状的植物和用于产生该植物的方法
CN107083386A (zh) 2008-08-25 2017-08-22 埃克斯雷德制药有限公司 阻止结缔组织生长因子的反义核苷酸及其用途
JP5653921B2 (ja) 2008-09-11 2015-01-14 キージーン・エン・フェー 特徴的なマーカー作製方法
CA2736473A1 (en) 2008-09-23 2010-04-01 Basf Plant Science Gmbh Plants with increased yield (lt)
MX2011002675A (es) 2008-09-24 2011-04-21 Basf Plant Science Gmbh Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas.
US8501805B2 (en) 2008-09-24 2013-08-06 Isis Pharmaceuticals, Inc. Substituted alpha-L-bicyclic nucleosides
DK2361256T3 (da) 2008-09-24 2013-07-01 Isis Pharmaceuticals Inc Cyclohexenyl-nukleinsyreanaloger
UA115019C2 (uk) 2008-09-26 2017-09-11 Басф Агрокемікал Продактс Б.В. Стійкий до гербіцидів ahas-мутант рослини brassica
SI2379084T1 (en) 2008-10-15 2018-04-30 Ionis Pharmaceuticals, Inc. Modulation of factor expression 11
DK2349310T3 (da) * 2008-10-20 2014-08-11 Moerae Matrix Inc Polypeptid til behandling eller forebyggelse af adhæsioner
AR075465A1 (es) 2008-10-22 2011-04-06 Basf Se Uso de herbicidas de sulfonilurea en plantas cultivadas
WO2010046422A2 (en) 2008-10-22 2010-04-29 Basf Se Use of auxin type herbicides on cultivated plants
AU2009306575B2 (en) 2008-10-23 2016-04-14 Basf Plant Science Gmbh Plants with increased yield (NUE)
AU2009306369A1 (en) 2008-10-23 2010-04-29 Basf Plant Science Gmbh A method for producing a transgenic cell with increased gamma-aminobutyric acid (GABA) content
CN102264374B (zh) 2008-10-24 2015-01-07 Isis制药公司 5′和2′双取代的核苷和由其制备的低聚化合物
EP2447274B1 (de) 2008-10-24 2017-10-04 Ionis Pharmaceuticals, Inc. Oligomerverbindungen und Verfahren
EP2821490A3 (de) 2008-10-30 2015-04-22 Pioneer Hi-Bred International Inc. Manipulation von Glutaminsynthetasen (GS) zur Verbesserung der Stickstoffnutzungseffizienz und des Kornertrags in höherentwickelten Pflanzen
EP2184351A1 (de) 2008-10-30 2010-05-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Polynukleotid-kondierende Caryophyllen-Synthase und ihre Verwendung
US20110247098A1 (en) 2008-11-12 2011-10-06 Basf Plant Science Gmbh Plants Having Enhanced Abiotic Stress Tolerance and/or Enhanced Yield-Related Traits and a Method for Making the Same
WO2010054513A1 (en) 2008-11-14 2010-05-20 Fujian Fuda Biotech Co. Ltd. A thermotolerant non-k12 escherichia coli phytase and its production
JP5749172B2 (ja) 2008-11-24 2015-07-15 ノースウェスタン ユニバーシティ 多価ｒｎａ−ナノ粒子組成物
CN104328137A (zh) 2008-12-03 2015-02-04 巴斯夫植物科学有限公司 具有增强的非生物胁迫耐受性和/或增强的产量相关性状的植物及其制备方法
JP6091752B2 (ja) 2008-12-04 2017-03-08 クルナ・インコーポレーテッド Ｅｐｏに対する天然アンチセンス転写物の抑制によるエリスロポエチン（ｅｐｏ）関連疾患の治療
US8431775B2 (en) 2008-12-04 2013-04-30 Pioneer Hi Bred International Inc Methods and compositions for enhanced yield by targeted expression of knotted1
WO2010065787A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
CN108042560A (zh) 2008-12-04 2018-05-18 库尔纳公司 通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1相关的疾病
DK2378875T3 (en) 2008-12-10 2018-09-03 Purdue Research Foundation CELLE-PERMEANT PEPTID-BASED INHIBITOR OF KINASES
EP2376638B1 (de) 2008-12-12 2013-08-14 BASF Plant Science GmbH Desaturasen und verfahren zur herstellung mehrfach ungesättigter fettsäuren in transgenen organismen
AU2009335740B2 (en) 2008-12-17 2016-04-21 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
WO2010069847A1 (en) 2008-12-17 2010-06-24 Basf Plant Science Gmbh Plants having enhanced yield-related traits and/or abiotic stress tolerance and a method for making the same
EP2204086A1 (de) 2009-01-02 2010-07-07 Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung (IPK) Sechszeilige Gerste
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
AU2010204723A1 (en) 2009-01-14 2011-08-18 The Salk Institute For Biological Studies Methods for screening and compounds that protect against amyloid diseases
BRPI1007465A2 (pt) 2009-01-28 2015-11-24 Basf Plant Science Co Gmbh método para realçar traços relacionados com o rendimento em plantas em relação às plantas de controle, para produzir uma planta transgênica tendo rendimento aumentado, molécula de ácido nucleico isolada, polipeptídio isolado, construçao, uso de uma construção e de um ácido nucleico, célula de planta, e, produtos
WO2010090969A1 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
US20120021515A1 (en) 2009-02-06 2012-01-26 Swayze Eric E Oligomeric compounds and methods
CN102439149B (zh) 2009-02-12 2018-01-02 库尔纳公司 通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
CN102387817B (zh) 2009-02-12 2018-01-30 库尔纳公司 通过抑制针对脑衍生神经营养因子(bdnf)的天然反义转录物来治疗bdnf相关的疾病
WO2010097343A1 (en) 2009-02-25 2010-09-02 Basf Plant Science Company Gmbh Plants having enhanced yield-related traits and a method for making the same
US8716553B2 (en) 2009-03-02 2014-05-06 Pioneer Hi Bred International Inc NAC transcriptional activators involved in abiotic stress tolerance
JP6250263B2 (ja) 2009-03-04 2017-12-20 クルナ・インコーポレーテッド サーチュイン１（ｓｉｒｔ１）に対する天然アンチセンス転写物の抑制によるｓｉｒｔ１関連疾患の治療
EP2408919B1 (de) 2009-03-16 2017-10-18 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
JP5904935B2 (ja) 2009-03-17 2016-04-20 クルナ・インコーポレーテッド デルタ様１ホモログ（ｄｌｋ１）に対する天然アンチセンス転写物の抑制によるｄｌｋ１関連疾患の治療
UA108071C2 (uk) 2009-04-14 2015-03-25 Піонер Хай-Бред Інтернешнл, Інк. Спосіб поліпшення витривалості до нестачі азоту у рослини
WO2010121956A1 (en) 2009-04-21 2010-10-28 Basf Plant Science Company Gmbh Rna-mediated induction of gene expression in plants
DE112010001705T5 (de) 2009-04-21 2013-01-24 Basf Plant Science Company Gmbh RNA-vermittelte lnduktion von Genexpression in Pflanzen
EP3248618A1 (de) 2009-04-22 2017-11-29 Massachusetts Institute Of Technology Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
BRPI1014386A2 (pt) 2009-04-29 2015-08-25 Basf Plant Science Co Gmbh Métodos para intensificar traços relacionados com o rendimento em plantas com relação às plantas de controle, construção, uso de uma construção, planta, parte de planta ou célula de planta, método para a produção de uma planta transgênica, partes colhíveis de uma planta, produtos, uso de um ácido nucleico, molécula de ácido nucleico isolada, e, polipeptídeo.
KR101647732B1 (ko) 2009-04-29 2016-08-16 바스프 플랜트 사이언스 게엠베하 향상된 수확량 관련 형질을 갖는 식물 및 이의 제조 방법
WO2010127195A2 (en) 2009-05-01 2010-11-04 Curna, Inc. Antisense oligonucleotides of hemoglobins
CA2760700A1 (en) 2009-05-04 2010-11-11 Pioneer Hi-Bred International, Inc. Yield enhancement in plants by modulation of ap2 transcription factor
AU2010244546A1 (en) 2009-05-06 2011-12-01 Basf Plant Science Company Gmbh Plants having enhanced yield-related traits and/or enhanced abiotic stress tolerance and a method for making the same
CN103223177B (zh) 2009-05-06 2016-08-10 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
WO2010129746A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
CA2762369C (en) 2009-05-18 2021-12-28 Joseph Collard Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
JP2012527248A (ja) 2009-05-22 2012-11-08 クルナ・インコーポレーテッド 転写因子ｅ３（ｔｆｅ３）に対する天然アンチセンス転写物の阻害によるｔｆｅ３およびインスリン受容体基質２（ｉｒｓ２）関連疾患の処置
US8791085B2 (en) 2009-05-28 2014-07-29 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
WO2010148065A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
JP5944311B2 (ja) 2009-06-16 2016-07-05 クルナ・インコーポレーテッド コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
MX2011013544A (es) 2009-06-19 2012-02-21 Basf Plant Science Co Gmbh Plantas que tienen mejores rasgos relacionados con el rendimiento y un metodo para producirlas.
EP2446036B1 (de) 2009-06-24 2017-03-01 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit tumornekrose faktor-rezeptor 2 (tnfr2) mittels hemmung des natürlichen antisense-transkripts gegen tnfr2
EP2446037B1 (de) 2009-06-26 2016-04-20 CuRNA, Inc. Behandlung von krankheiten im zusammenhang mit dem down-syndrom-gen durch hemmung des natürlichen antisense-transkripts zu einem down-syndrom-gen
CA2764073A1 (en) 2009-06-30 2011-01-20 E. I. Du Pont De Nemours And Company Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding cytosolic pyrophosphatase
EP2272862B1 (de) 2009-07-10 2012-03-21 Freie Universität Berlin rock2 und rock3, zwei neue Gain-of-Function-Varianten der Cytokininrezeptoren AHK2 und AHK3
EP2275564A1 (de) 2009-07-17 2011-01-19 Freie Universität Berlin Mittel und Verfahren zur Produktion von transgenen Pflanzen, die gegenüber Kohlhernie resistent sind
AU2010275363A1 (en) 2009-07-23 2012-02-02 Basf Plant Science Company Gmbh Plants with increased yield
EP2456874A1 (de) 2009-07-24 2012-05-30 Pioneer Hi-Bred International Inc. Verwendung von dimerisatonsdomänenkomponentenstapeln zur modulation einer pflanzenarchitektur
WO2011017132A2 (en) * 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2011017492A2 (en) 2009-08-05 2011-02-10 Pioneer Hi-Bred International, Inc. Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants
WO2011017516A2 (en) 2009-08-05 2011-02-10 Curna, Inc. Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
EP2462153B1 (de) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclische cyclohexosenukleinsäureanaloga
GB0914012D0 (en) 2009-08-11 2009-09-16 Plant Bioscience Ltd Stress tolerant plants
EA201200284A1 (ru) 2009-08-19 2013-03-29 Басф Плант Сайенс Компани Гмбх Растения, имеющие улучшенные характеристики, связанные с урожаем, и способ создания таких
US20110061132A1 (en) 2009-08-20 2011-03-10 Pioneer Hi-Bred International, Inc. Functional expression of yeast nitrate transporter (ynt1) in maize to improve nitrate uptake
EP2470657B1 (de) 2009-08-25 2019-10-23 CuRNA, Inc. Behandlung von iqgap ('iq-motiv-haltiges gtpase-aktivierendes protein')-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen iqgap
JP2013502914A (ja) 2009-08-31 2013-01-31 ビーエーエスエフ プラント サイエンス カンパニー ゲーエムベーハー 多価不飽和脂肪酸合成の増強を促進する植物の種子特異的遺伝子発現を増強する調節核酸分子
CN105132425B (zh) 2009-08-31 2018-10-02 巴斯夫植物科学有限公司 用于增强植物中组成型基因表达的调节性核酸分子
EP2473608B1 (de) 2009-08-31 2017-07-05 BASF Plant Science Company GmbH Regulatorische nukleinsäuremoleküle für erhöhte keimspezifische und/oder keimbevorzugte genexpression bei pflanzen
DK2473522T3 (en) 2009-09-02 2016-11-28 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
AU2010299857A1 (en) 2009-09-25 2012-04-19 Basf Plant Science Company Gmbh Plants having enhanced yield-related traits and a method for making the same
EP2480566A1 (de) 2009-09-25 2012-08-01 BASF Plant Science Company GmbH Pflanzen mit verbesserten ertragseigenschaften und verfahren zu ihrer herstellung
AR078502A1 (es) 2009-10-02 2011-11-09 Pioneer Hi Bred Int Regulacion hacia abajo de acc (acido 1-aminociclopropano-1-carboxilico) sintasa para el rendimiento mejorado de plantas
CN102711826B (zh) 2009-10-22 2017-03-29 霍夫曼-拉罗奇有限公司 用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
AU2010309990A1 (en) 2009-10-22 2012-05-24 Basf Plant Science Company Gmbh Plants having enhanced yield-related traits and a method for making the same
AU2010313154B2 (en) 2009-10-30 2016-05-12 Northwestern University Templated nanoconjugates
AR078829A1 (es) 2009-10-30 2011-12-07 Du Pont Plantas y semillas con niveles alterados de compuesto de almacenamiento, construcciones relacionadas y metodos relacionados con genes que codifican proteinas similares a las aldolasas bacterianas de la clase ii del acido 2,4- dihidroxi-hept-2-eno-1,7-dioico
MX2012005508A (es) 2009-11-13 2012-07-23 Basf Plant Science Co Gmbh Plantas que tienen mejores rasgos relacionados con el rendimiento y un metodo para producirlas.
US8697858B2 (en) 2009-11-13 2014-04-15 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating influenza viral infection
DE112010004469T5 (de) 2009-11-17 2012-09-06 Basf Plant Science Company Gmbh Pflanzen mit erhöhtem Ertrag
ES2760911T3 (es) * 2009-11-23 2020-05-18 Cibus Europe Bv Métodos y composiciones para producir escualeno empleando levaduras
WO2011066503A2 (en) 2009-11-30 2011-06-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US9173895B2 (en) 2009-12-16 2015-11-03 Curna, Inc. Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
EP2515947B1 (de) 2009-12-23 2021-10-06 CuRNA, Inc. Behandlung von durch das uncoupling protein 2 (ucp2) bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts für ucp2
ES2661387T3 (es) 2009-12-23 2018-03-28 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf
AU2010343143A1 (en) 2009-12-28 2012-06-28 Pioneer Hi-Bred International, Inc. Sorghum fertility restorer genotypes and methods of marker-assisted selection
WO2011090740A2 (en) 2009-12-29 2011-07-28 Opko Curna, Llc Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
WO2011090741A2 (en) 2009-12-29 2011-07-28 Opko Curna, Llc TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
CA2786001A1 (en) 2009-12-31 2011-07-07 Pioneer Hi-Bred International, Inc. Engineering plant resistance to diseases caused by pathogens
ES2664605T3 (es) 2010-01-04 2018-04-20 Curna, Inc. Tratamiento de enfermedades relacionadas con el factor 8 regulador del interferón (irf8) mediante inhibición del transcrito antisentido natural al gen irf8
US8912157B2 (en) 2010-01-06 2014-12-16 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
CA2786741A1 (en) 2010-01-06 2011-07-14 Pioneer Hi-Bred International, Inc. Identification of diurnal rhythms in photosynthetic and non-photosynthetic tissues from zea mays and use in improving crop plants
WO2011085102A1 (en) 2010-01-11 2011-07-14 Isis Pharmaceuticals, Inc. Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
US9200277B2 (en) 2010-01-11 2015-12-01 Curna, Inc. Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
US20110236325A1 (en) 2010-01-21 2011-09-29 NellOne Therapeutics, Inc. Methods to treat or prevent a skin condition using a nell1 peptide
JP5981850B2 (ja) 2010-01-25 2016-08-31 カッパーアールエヌエー，インコーポレイテッド ＲＮａｓｅＨ１に対する天然アンチセンス転写物の阻害によるＲＮａｓｅＨ１関連疾患の治療
CA2818599A1 (en) 2010-01-26 2011-08-04 Bailin Li Polynucleotide and polypeptide sequences associated with herbicide tolerance
CN102844435B (zh) 2010-02-22 2017-05-10 库尔纳公司 通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
KR20130004579A (ko) 2010-02-23 2013-01-11 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
DE112011100643T5 (de) 2010-02-24 2013-01-10 Basf Plant Science Company Gmbh Pflanzen mit gesteigerten Ertragsmerkmalen und Verfahren zu deren Herstellung
MX2012009524A (es) 2010-02-24 2012-09-12 Basf Plant Science Co Gmbh Plantas que tienen mejores rasgos relacionados con el rendimiento y un metodo para producirlas.
EP2361985A1 (de) 2010-02-26 2011-08-31 BASF Plant Science Company GmbH Pflanzen mit verbesserten Ertragseigenschaften und Verfahren zu ihrer Herstellung
EP2361927A1 (de) 2010-02-26 2011-08-31 BASF Plant Science Company GmbH Pflanzen mit verbesserten Ertragseigenschaften und Verfahren zu ihrer Herstellung
BR112012022045A8 (pt) 2010-03-03 2018-06-19 Du Pont ''planta transgênica,semente transgênica,método para produzir uma planta transgênica,método para produzir sementes transgênicas,produto e/ou subproduto,polinucleotídeo isolado e planta ou semente''.
GB201003702D0 (en) 2010-03-05 2010-04-21 Univ Warwick Molecular engineering of a floral inducer for crop improvement
US9068185B2 (en) 2010-03-12 2015-06-30 Sarepta Therapeutics, Inc. Antisense modulation of nuclear hormone receptors
ES2743600T3 (es) 2010-03-12 2020-02-20 Brigham & Womens Hospital Inc Métodos de tratamiento de los trastornos inflamatorios vasculares
US9193752B2 (en) 2010-03-17 2015-11-24 Isis Pharmaceuticals, Inc. 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011114305A1 (en) 2010-03-18 2011-09-22 Basf Plant Science Company Gmbh Plants having enhanced yield-related traits and method for making the same
EP2547195A4 (de) 2010-03-18 2014-01-08 Basf Plant Science Co Gmbh Pflanzen mit verbesserten ertragseigenschaften und verfahren zu ihrer herstellung
WO2011114312A1 (en) 2010-03-19 2011-09-22 Basf Plant Science Company Gmbh Plants having enhanced yield-related traits and method for making same
CN102892891A (zh) 2010-03-19 2013-01-23 巴斯夫植物科学有限公司 具有增强的产量相关性状的植物和用于产生该植物的方法
EP2371845A1 (de) 2010-03-22 2011-10-05 BASF Plant Science Company GmbH Installations dotées de caractéristiques de rendement améliorées et procédé de fabrication de celles-ci
CN102858979B (zh) 2010-04-09 2018-01-26 库尔纳公司 通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病
EP2385129A1 (de) 2010-05-03 2011-11-09 BASF Plant Science Company GmbH Verbessertes Verfahren zur Genregulierung in Pflanzen
EP2563380B1 (de) 2010-04-26 2018-05-30 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten der cysteinyl-trna-synthetase
EP2563381B1 (de) 2010-04-27 2017-08-09 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von isoleucyl-trna-synthetasen
US8993738B2 (en) 2010-04-28 2015-03-31 Isis Pharmaceuticals, Inc. Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
US9127033B2 (en) 2010-04-28 2015-09-08 Isis Pharmaceuticals, Inc. 5′ modified nucleosides and oligomeric compounds prepared therefrom
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
CN103038345B (zh) 2010-04-29 2017-07-21 Ionis制药公司 转甲状腺素蛋白表达的调节
CA2797393C (en) 2010-04-29 2020-03-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
US9034321B2 (en) 2010-05-03 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
KR101915115B1 (ko) 2010-05-03 2018-11-05 큐알엔에이, 인크. 시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
JP5976638B2 (ja) 2010-05-03 2016-08-23 エータイアー ファーマ， インコーポレイテッド アルギニルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2566496B1 (de) 2010-05-03 2018-02-28 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von methionyl-trna-synthetasen
MX342239B (es) 2010-05-03 2016-09-21 Genentech Inc * Composiciones y metodos para el diagnostico y tratamiento de tumores.
JP2013529074A (ja) 2010-05-04 2013-07-18 ビーエーエスエフ ソシエタス・ヨーロピア 除草剤に対する耐性が増加した植物
EP2566499B1 (de) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten aus einem p38-multi-trna-synthetase-komplex
EA201291178A1 (ru) 2010-05-06 2013-04-30 Пайонир Хай-Бред Интернэшнл, Инк. Ген и белок acc-синтазы 3 маиса и их применения
GB201007834D0 (en) 2010-05-11 2010-06-23 Vib Vzw Growth promoting fusion proteins
CN109593814A (zh) 2010-05-12 2019-04-09 哥伦比亚大学纽约管理委员会 筛选分析、鉴别药剂的方法及药物组合物
WO2011143608A1 (en) 2010-05-13 2011-11-17 Avi Biopharma, Inc. Antisense modulation of interleukins 17 and 23 signaling
US8945541B2 (en) 2010-05-14 2015-02-03 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
TWI586356B (zh) 2010-05-14 2017-06-11 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
JP6027965B2 (ja) 2010-05-17 2016-11-16 エータイアー ファーマ， インコーポレイテッド ロイシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
CN107412251A (zh) 2010-05-26 2017-12-01 库尔纳公司 通过抑制无调同源物1(atoh1)的天然反义转录物而治疗atoh1相关疾病
EP2575856B1 (de) 2010-05-27 2017-08-16 aTyr Pharma, Inc. Therapeutische, diagnostische und antikörperhaltige zusammensetzungen in zusammenhang mit proteinfragmenten von glutaminyl-trna-synthetasen
US8957200B2 (en) 2010-06-07 2015-02-17 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2582396A4 (de) 2010-06-15 2014-01-01 Medgenics Medical Israel Ltd Heilmittelformulierungen mit langzeitwirkung
CA2801422A1 (en) 2010-06-24 2011-12-29 Basf Plant Science Company Gmbh Plants having enhanced yield-related traits and method for making the same
CA2801688A1 (en) 2010-06-25 2011-12-29 Basf Plant Science Company Gmbh Plants with enhanced yield-related traits and producing method thereof
WO2012003207A2 (en) 2010-07-01 2012-01-05 E. I. Du Pont De Nemours And Company Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding pae and pae-like polypeptides
CN103124738B (zh) 2010-07-08 2016-08-17 拜尔作物科学公司 芥子油苷转运蛋白及其用途
WO2012021247A2 (en) 2010-07-12 2012-02-16 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
JP5998131B2 (ja) 2010-07-14 2016-09-28 カッパーアールエヌエー，インコーポレイテッド Ｄｉｓｃｓｌａｒｇｅｈｏｍｏｌｏｇ（ｄｌｇ）ｄｌｇ１への天然アンチセンス転写物の阻害によるｄｌｇ関連疾患の治療
BR112013000992A2 (pt) 2010-07-16 2016-05-24 Basf Plant Science Co Gmbh métodos para intensificar traços relacionados ao rendimento em plantas, construtos, usos de um construto, plantas, parte de plantas, células de plantas transformadas, métodos para a produção de uma planta transgênica, plantas transgênicas, partes colhíveis e produtos derivados de uma planta, usos de um ácido nucleico, moléculas de ácido nucleico isolado, polipeptídeos isolados e uso de ácidos nucleicos de rna helicase dead-box
US20120122223A1 (en) 2010-08-03 2012-05-17 Cibus Us Llc Mutated protoporphyrinogen ix oxidase (ppx) genes
UA112969C2 (uk) 2010-08-03 2016-11-25 Сібас Юс Ллс Рослина, стійка до одного або більше ррх-інгібуючих гербіцидів, яка містить мутантний ген протопорфіриноген ix оксидази (ррх)
AU2011289286B2 (en) 2010-08-13 2015-02-12 Pioneer Hi-Bred International, Inc. Methods and compositions for targeting sequences of interest to the chloroplast
US20140026257A1 (en) 2010-08-24 2014-01-23 Basf Plant Science Company Gmbh Plants Having Enhanced Yield-Related Traits and Method for Making the Same
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
EP2426204A1 (de) 2010-09-02 2012-03-07 Ludwig-Maximilians-Universität München Spontane Knöllchenorganogenese in Pflanzen
WO2012028673A1 (en) 2010-09-02 2012-03-08 Ludwig-Maximilians-Universitaet Muenchen Spontaneous organogenesis in plants
DK2625197T3 (en) 2010-10-05 2016-10-03 Genentech Inc Smoothened MUTANT AND METHODS OF USING THE SAME
US8993533B2 (en) 2010-10-06 2015-03-31 Curna, Inc. Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
US9222088B2 (en) 2010-10-22 2015-12-29 Curna, Inc. Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
CN103201387B (zh) 2010-10-27 2018-02-02 库尔纳公司 通过抑制干扰素相关发育调节因子1(ifrd1)的天然反义转录物而治疗ifrd1相关疾病
US20130298288A1 (en) 2010-11-10 2013-11-07 Basf Plant Science Company Gmbh Plants Having Enhanced Yield-Related Traits and Method for Making the Same
EP2638163B1 (de) 2010-11-12 2017-05-17 The General Hospital Corporation Polycomb-assoziierte nicht-kodierende rnas
US8609621B2 (en) 2010-11-15 2013-12-17 E I Du Pont De Nemours And Company Acid-cleavable linkers exhibiting altered rates of acid hydrolysis
CA3077910A1 (en) 2010-11-17 2012-05-24 Ionis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
KR102010598B1 (ko) 2010-11-23 2019-08-13 큐알엔에이, 인크. Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
US9834778B2 (en) 2010-12-06 2017-12-05 Basf Plant Science Company Gmbh Synthetic arcelin-5 promoter and methods of use thereof
EA029356B1 (ru) 2010-12-16 2018-03-30 Басф Агро Б.В. Растения с повышенной устойчивостью к гербицидам
HUE042592T2 (hu) 2010-12-22 2019-07-29 Pioneer Hi Bred Int A Sclerotiniá-val szembeni teljes szántóföldi rezisztenciával összefüggõ QTL-ek és rezisztencia azonosítási módszerei
WO2012097261A2 (en) 2011-01-14 2012-07-19 The General Hospital Corporation Methods targeting mir-128 for regulating cholesterol/lipid metabolism
WO2012098517A1 (en) 2011-01-20 2012-07-26 Basf Plant Science Company Gmbh Plants having enhanced yield-related traits and method for making the same
US9688719B2 (en) 2011-01-27 2017-06-27 Ramot At Tel-Aviv University Ltd. Glycogen synthase kinase-3 inhibitors
WO2012101599A2 (en) 2011-01-27 2012-08-02 Ramot At Tel-Aviv University Ltd. Glycogen synthase kinase-3 inhibitors
EP3682731A1 (de) 2011-02-01 2020-07-22 Colorado Wheat Research Foundation, Inc. Acetyl-coenzym-a-carboxylase-herbizidresistente pflanzen
CN103391777A (zh) 2011-02-02 2013-11-13 普林斯顿大学理事会 作为病毒产生调节剂的去乙酰化酶调节剂
US9173894B2 (en) 2011-02-02 2015-11-03 Excaliard Pharamaceuticals, Inc. Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
US9273336B2 (en) 2011-02-21 2016-03-01 E. I. Du Pont De Nemours And Company Recombinant host cells having an increase in buoyant density
AR085394A1 (es) 2011-02-25 2013-09-25 Univ Nac De La Plata Unlp Proteasa de plantas
DE112012001017T5 (de) 2011-02-28 2013-12-19 Basf Plant Science Company Gmbh Pflanzen mit gesteigerten Ertragsmerkmalen und Verfahren zu deren Herstellung
DE112012001020T5 (de) 2011-02-28 2013-12-19 Basf Plant Science Company Gmbh Pflanzen mit gesteigerten Ertragsmerkmalen und Verfahren zu deren Herstellung
AU2012222946A1 (en) 2011-03-01 2013-09-19 Basf Plant Science Company Gmbh Plants having enhanced yield-related traits and producing methods thereof
SG10201604560TA (en) 2011-04-12 2016-07-28 Moerae Matrix Inc Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
EP2794643A1 (de) 2011-04-29 2014-10-29 Pioneer Hi-Bred International Inc. Abwärtsregulation eines homöodomäne-leucin-zipper-homöoboxgens der klasse i für verbesserten plfanzenertrag
WO2012156760A1 (en) 2011-05-19 2012-11-22 Consejo Superior De Investigaciones Cientificas Process for modifying the architecture and improving the yield of crop plants
WO2012170347A1 (en) 2011-06-09 2012-12-13 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
CN103620036B (zh) 2011-06-09 2016-12-21 库尔纳公司 通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病
EP2721160A2 (de) 2011-06-14 2014-04-23 Synthon Biopharmaceuticals B.V. Zusammensetzungen und verfahren zur herstellung und bioabdichtung auxotropher transgener pflanzen
US20130097734A1 (en) 2011-07-12 2013-04-18 Two Blades Foundation Late blight resistance genes
MX347810B (es) 2011-07-15 2017-05-15 Syngenta Participations Ag Métodos para mejorar el rendimiento y la tolerancia al estrés en una planta.
WO2013012643A1 (en) 2011-07-15 2013-01-24 Syngenta Participations Ag Polynucleotides encoding trehalose-6-phosphate phosphatase and methods of use thereof
BR112014002342A2 (pt) 2011-08-01 2020-11-17 Basf Plant Science Company Gmbh moléculas terminais, método de identificação e isolamento de moléculas terminais, método de produção de moléculas terminais recombinantes, método de produção de plantas ou suas partes com expressão amplificada, construção de expressão recombinante, vetor de expressão recombinante, célula transgênica, planta transgênica ou sua parte, cultivo de células transgênicas, sementes trasngênicas, partes ou material de propagação derivados de uma célula ou planta transgênica ou sua parte, uso da molécula terminal e método de produção de produto agrícola
US9889209B2 (en) 2011-09-14 2018-02-13 Northwestern University Nanoconjugates able to cross the blood-brain barrier
EP2756080B1 (de) 2011-09-14 2019-02-20 Translate Bio MA, Inc. Multimere oligonukleotidverbindungen
EP2766482B1 (de) 2011-10-11 2016-12-07 The Brigham and Women's Hospital, Inc. Mikro-rnas in neurodegenerativen erkrankungen
BR112014009968A2 (pt) 2011-10-25 2017-07-04 Du Pont método para redução do teor de acetato, arabinosidase e/ou ferulato em uma planta, método de modulação da concentração de carboidratos da planta em uma planta transgénica, método para alterar o teor de acetila e de reticulação nos tecidos das plantas, método para a produção de biomassa para a produção de biocombustíveis ou silagem, produto, forragem de planta
CN104093842B (zh) 2011-10-31 2016-12-07 先锋国际良种公司 改善植物耐旱性、氮利用效率和产量
CA2895077A1 (en) 2011-12-12 2013-06-20 Beverly Packard In vivo delivery of oligonucleotides
BR112014020119A2 (pt) 2012-02-13 2020-10-27 Gamida-Cell Ltd cultura de células-tronco mesenquimais
US9452218B2 (en) 2012-03-09 2016-09-27 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
CN104703998B (zh) 2012-03-13 2020-08-21 先锋国际良种公司 植物中雄性育性的遗传减少
WO2013138309A1 (en) 2012-03-13 2013-09-19 Pioneer Hi-Bred International, Inc. Genetic reduction of male fertility in plants
EP2825648B1 (de) 2012-03-15 2018-09-05 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem brain-derived neurotrophen faktor (bdnf) mittels hemmung des natürlichen antisense-transkripts gegen bdnf
WO2013138662A1 (en) 2012-03-16 2013-09-19 4S3 Bioscience, Inc. Antisense conjugates for decreasing expression of dmpk
WO2013154798A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013154799A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleosides and oligomeric compounds prepared therefrom
WO2013159091A2 (en) 2012-04-20 2013-10-24 Aptamir Therapeutics, Inc. Mirna modulators of thermogenesis
EP2841572B1 (de) 2012-04-27 2019-06-19 Duke University Genetische korrektur mutierter gene
AU2013262649A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating smn gene family expression
CN104583398A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节基因表达的组合物和方法
US10045499B2 (en) 2012-05-24 2018-08-14 Iowa State University Research Foundation, Inc. Arabidopsis nonhost resistance gene(s) and use thereof to engineer disease resistant plants
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
AR091489A1 (es) 2012-06-19 2015-02-11 Basf Se Plantas que tienen una mayor tolerancia a herbicidas inhibidores de la protoporfirinogeno oxidasa (ppo)
EP2677035A1 (de) 2012-06-22 2013-12-25 BASF Plant Science Company GmbH Pflanzen mit verbesserten Ertragseigenschaften und Verfahren zu ihrer Herstellung
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
EP2880161A1 (de) 2012-08-03 2015-06-10 Aptamir Therapeutics, Inc. Abgabe von zellspezifischen mirna-modulatoren zur behandlung von adipositas und verwandten erkrankungen
US9403865B2 (en) 2012-08-15 2016-08-02 Ionis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified capping protocols
EP2885411B1 (de) 2012-08-16 2018-12-05 VIB vzw Mittel und verfahren zur änderung des lignin-signalwegs bei pflanzen
WO2014037735A1 (en) 2012-09-10 2014-03-13 University Of Leicester Atsp1, an e3 ubiquitin ligase, and its use
US9029335B2 (en) 2012-10-16 2015-05-12 Isis Pharmaceuticals, Inc. Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
AU2013336237A1 (en) 2012-10-22 2015-06-11 Sabag-Rfa Ltd A system for delivering therapeutic agents into living cells and cells nuclei
WO2014081673A2 (en) 2012-11-20 2014-05-30 Pioneer Hi-Bred International, Inc. Engineering plants for efficient uptake and utilization of urea to improve crop production
BR112015015055A2 (pt) 2012-12-21 2017-10-03 Pioneer Hi Bred Int Método para desintoxicar um herbicida análogo de auxina, método para controlar pelo menos uma erva em uma área de cultivo, método para testar uma resposta de planta a um ou mais compostos
EP2754715A1 (de) 2013-01-11 2014-07-16 Consejo Superior De Investigaciones Científicas (CSIC) Stresstolerante Pflanzen
CN104994725B (zh) 2013-01-29 2022-07-01 巴斯夫植物科学有限公司 表达hcp6的抗真菌植物
WO2014118018A1 (en) 2013-01-29 2014-08-07 Basf Plant Science Company Gmbh Fungal resistant plants expressing ein2
CN104955324A (zh) 2013-01-29 2015-09-30 巴斯夫植物科学有限公司 表达hcp7的抗真菌植物
WO2014121436A1 (en) 2013-02-05 2014-08-14 Plant Bioscience Limited Transgenic plants
CN105008542B (zh) 2013-03-08 2020-02-07 巴斯夫植物科学有限公司 表达MybTF的抗真菌性植物
US20160002648A1 (en) 2013-03-11 2016-01-07 Mei Guo Genes for improving nutrient uptake and abiotic stress tolerance in plants
WO2014164466A1 (en) 2013-03-12 2014-10-09 E. I. Du Pont De Nemours And Company Methods for the identification of variant recognition sites for rare-cutting engineered double-strand-break-inducing agents and compositions and uses thereof
US9803214B2 (en) 2013-03-12 2017-10-31 Pioneer Hi-Bred International, Inc. Breeding pair of wheat plants comprising an MS45 promoter inverted repeat that confers male sterility and a construct that restores fertility
WO2014164074A1 (en) 2013-03-13 2014-10-09 Pioneer Hi-Bred International, Inc. Enhanced nitrate uptake and nitrate translocation by over-expressing maize functional low-affinity nitrate transporters in transgenic maize
WO2014164116A1 (en) 2013-03-13 2014-10-09 Pioneer Hi-Bred International, Inc. Functional expression of bacterial major facilitator superfamily (sfm) gene in maize to improve agronomic traits and grain yield
PE20151922A1 (es) 2013-03-14 2016-01-16 Cibus Us Llc Genes de aleno oxido sintasa 2 (aos2) mutados
CA2903693A1 (en) 2013-03-14 2014-10-02 Pioneer Hi-Bred International, Inc. Maize stress related transcription factor 18 and uses thereof
US9957515B2 (en) 2013-03-15 2018-05-01 Cibus Us Llc Methods and compositions for targeted gene modification
CA2903297A1 (en) 2013-03-15 2014-09-25 Pioneer Hi-Bred International, Inc. Modulation of acc deaminase expression
US20160017350A1 (en) 2013-03-15 2016-01-21 Pioneer Hi-Bred International, Inc. Compositions and methods of use of acc oxidase polynucleotides and polypeptides
AU2014233465A1 (en) 2013-03-15 2015-09-03 Cibus Europe B.V. Targeted gene modification using oligonucleotide-mediated gene repair
US10287594B2 (en) * 2013-03-15 2019-05-14 Cibus Us Llc Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair
EP2976429B1 (de) 2013-03-21 2017-04-19 VIB vzw Vorrichtung und verfahren zur reduktion von fotorespiration in nutzpflanzenkulturen
RU2019110030A (ru) 2013-05-01 2019-05-06 Ионис Фармасьютикалз, Инк. Композиции и способы
US20160129089A1 (en) 2013-06-13 2016-05-12 Antisense Therapeutics Ltd Combination therapy
EP2816115A1 (de) 2013-06-17 2014-12-24 BASF Plant Science Company GmbH Pflanzen mit einem oder mehreren Merkmalen eines erhöhten Ertrages und Verfahren zu deren Herstellung
US9718859B2 (en) 2013-06-24 2017-08-01 Ramot At Tel-Aviv University Ltd. Glycogen synthase kinase-3 inhibitors
WO2015006105A1 (en) 2013-07-09 2015-01-15 Board Of Trustees Of Michigan State University Transgenic plants produced with a k-domain, and methods and expression cassettes related thereto
US11459579B2 (en) 2013-07-09 2022-10-04 Board Of Trustees Of Michigan State University Transgenic plants produced with a K-domain, and methods and expression cassettes related thereto
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
CA2844640A1 (en) 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
EP2896698A1 (de) 2014-01-17 2015-07-22 BASF Plant Science Company GmbH Pflanzen mit einer oder mehreren Merkmalen zum erhöhten Ertrag und Verfahren zu deren Herstellung
US20170166920A1 (en) 2014-01-30 2017-06-15 Two Blades Foundation Plants with enhanced resistance to phytophthora
EP3099333B8 (de) 2014-01-31 2020-12-30 Temple University of the Commonwealth System of Higher Education Bag3 als target zur behandlung von herzinsuffizienz
ES2694857T3 (es) 2014-02-04 2018-12-27 Genentech, Inc. Smoothened mutante y métodos de uso de la misma
RS65213B1 (sr) 2014-03-14 2024-03-29 Cibus Us Llc Postupci i kompozicije za povećanje efikasnosti ciljane modifikacije gena korišćenjem reparacije gena posredovane oligonukleotidima
US10036019B2 (en) 2014-03-17 2018-07-31 Ionis Pharmaceuticals, Inc. Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
US10006027B2 (en) 2014-03-19 2018-06-26 Ionis Pharmaceuticals, Inc. Methods for modulating Ataxin 2 expression
IL247600B (en) 2014-03-19 2022-06-01 Ionis Pharmaceuticals Inc Preparations for the modulation of ataxin 2 expression
HRP20220798T1 (hr) 2014-04-01 2022-10-14 Biogen Ma Inc. Pripravci za modulaciju ekspresije sod-1
WO2015150465A2 (en) 2014-04-03 2015-10-08 Basf Se Plants having increased tolerance to herbicides
US10221416B2 (en) 2014-04-24 2019-03-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising alpha-beta-constrained nucleic acid
CN106232804B (zh) 2014-05-01 2019-10-25 Ionis制药公司 用于调节补体因子b表达的组合物和方法
WO2015171603A1 (en) 2014-05-06 2015-11-12 Two Blades Foundation Methods for producing plants with enhanced resistance to oomycete pathogens
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
ES2908962T3 (es) 2014-06-10 2022-05-04 Univ Erasmus Med Ct Rotterdam Oligonucleótidos antisentido útiles en el tratamiento de la enfermedad de Pompe
EP3760208B1 (de) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting von humanem satellit ii (hsatii)
WO2015200901A1 (en) 2014-06-26 2015-12-30 The Trustees Of Columbia University In The City Of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
CA2954201A1 (en) 2014-07-08 2016-01-14 Vib Vzw Means and methods to increase plant yield
US20170142942A1 (en) 2014-07-14 2017-05-25 Washington State University Nanos knock-out that ablates germline cells
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
WO2016049512A1 (en) 2014-09-26 2016-03-31 University Of Massachusetts Rna-modulating agents
CN107250355B (zh) 2014-10-06 2021-07-16 奥驰亚客户服务有限公司 烟草植物中腋芽生长的遗传控制
SG11201703939XA (en) 2014-11-17 2017-06-29 Moerae Matrix Inc Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
CN107106493A (zh) 2014-11-21 2017-08-29 西北大学 球形核酸纳米颗粒缀合物的序列特异性细胞摄取
WO2016100309A1 (en) 2014-12-16 2016-06-23 Pioneer Hi-Bred International, Inc. Restoration of male fertility in wheat
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
US10793855B2 (en) 2015-01-06 2020-10-06 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
WO2016115490A1 (en) 2015-01-16 2016-07-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of dux4
WO2016116870A1 (en) 2015-01-21 2016-07-28 Basf Se Plants having increased tolerance to herbicides
WO2016124920A1 (en) 2015-02-03 2016-08-11 The Institute Of Genetics And Developmental Biology Rice plants with altered seed phenotype and quality
WO2016124918A1 (en) 2015-02-03 2016-08-11 The Institute Of Genetics And Developmental Biology Plants with increased seed size
BR112017016688B1 (pt) 2015-02-04 2024-01-23 Basf Plant Science Company Gmbh Método para aumentar a resistência fúngica, método para a produção de um produto e método para criar uma planta resistente a fungos
GB201501941D0 (en) 2015-02-05 2015-03-25 British American Tobacco Co Method
WO2016130600A2 (en) 2015-02-09 2016-08-18 Duke University Compositions and methods for epigenome editing
AR103649A1 (es) 2015-02-11 2017-05-24 Basf Se Hidroxifenilpiruvato dioxigenasas resistentes a herbicidas
GB201502409D0 (en) 2015-02-13 2015-04-01 British American Tobacco Co Method
US11129844B2 (en) 2015-03-03 2021-09-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating MECP2 expression
SG11201707281QA (en) 2015-03-12 2017-10-30 Moerae Matrix Inc Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
MX2017011976A (es) 2015-03-18 2018-02-09 Basf Se Microorganismo recombinante para la produccion mejorada de quimicos finos.
EP3283502A4 (de) 2015-04-07 2019-04-03 The General Hospital Corporation Verfahren zur reaktivierung von genen auf dem inaktiven x-chromosom
WO2016167780A1 (en) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
CN107709564B (zh) 2015-05-09 2021-11-02 双刃基金会 来自少花龙葵的抗晚疫病基因及使用方法
US10519474B2 (en) 2015-06-04 2019-12-31 Basf Se Recombinant microorganism for improved production of fine chemicals
MY189932A (en) 2015-06-12 2022-03-22 Basf Se Recombinant microorganism for improved production of alanine
AU2016282986A1 (en) 2015-06-26 2018-02-01 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
WO2017004243A1 (en) 2015-06-29 2017-01-05 Caris Science, Inc. Therapeutic oligonucleotides
AU2016298317B2 (en) 2015-07-28 2021-02-18 Caris Science, Inc. Targeted oligonucleotides
EP3353303B1 (de) 2015-09-25 2023-08-02 Ionis Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur modulation von ataxin 3-expression
WO2017062790A1 (en) 2015-10-09 2017-04-13 Two Blades Foundation Cold shock protein receptors and methods of use
WO2017066497A2 (en) 2015-10-13 2017-04-20 Duke University Genome engineering with type i crispr systems in eukaryotic cells
CA3007424A1 (en) 2015-11-05 2017-05-11 Children's Hospital Los Angeles "mobilizing leukemia cells"
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
EP3389670A4 (de) 2015-12-04 2020-01-08 Ionis Pharmaceuticals, Inc. Verfahren zur behandlung von brustkrebs
US10993995B2 (en) 2015-12-07 2021-05-04 Erasmus University Medical Center Rotterdam Enzymatic replacement therapy and antisense therapy for pompe disease
CA3006599A1 (en) 2016-01-05 2017-07-13 Ionis Pharmaceuticals, Inc. Methods for reducing lrrk2 expression
AU2017213826A1 (en) 2016-02-04 2018-08-23 Curis, Inc. Mutant smoothened and methods of using the same
US11542515B2 (en) 2016-02-09 2023-01-03 Cibus Us Llc Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair
CA3054284A1 (en) 2016-02-25 2017-08-31 The Brigham And Women's Hospital, Inc. Treatment methods for fibrosis targeting smoc2
US10731173B2 (en) 2016-03-11 2020-08-04 Altria Client Services Llc Compositions and methods for producing tobacco plants and products having reduced or eliminated suckers
WO2017161172A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Methods of modulating keap1
WO2017161168A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Modulation of dyrk1b expression
CA3018066A1 (en) 2016-03-18 2017-09-21 Caris Science, Inc. Oligonucleotide probes and uses thereof
WO2017167623A1 (en) 2016-03-30 2017-10-05 Basf Se Fermentative production of n-butylacrylate using alcohol acyl transferase enzymes
WO2017184500A1 (en) 2016-04-18 2017-10-26 Bloomsburg University of Pennsylvania Compositions and methods of delivering molecules to plants
US11608499B2 (en) 2016-04-29 2023-03-21 Basf Plant Science Company Gmbh Methods for modification of target nucleic acids
EP3054014A3 (de) 2016-05-10 2016-11-23 BASF Plant Science Company GmbH Benutzung einer fungizids auf transgenen pflanzen
BR112018072473A2 (pt) 2016-05-20 2019-02-19 Basf Agro Bv molécula de ácido nucleico, cassete de expressão, célula vegetal, planta, semente, métodos para expressar um ácido nucleico, produzir uma planta, controlar vegetação e cultivar a planta, combinação útil para o controle, processo para preparar uma combinação e uso de uma combinação
US10897903B2 (en) 2016-05-24 2021-01-26 Basf Se Method for controlling PPO resistant weeds
US11293017B2 (en) 2016-05-25 2022-04-05 Caris Science, Inc. Oligonucleotide probes and uses thereof
KR102538812B1 (ko) 2016-05-26 2023-06-01 넌헴스 비.브이. 씨없는 과실 생산 식물
US11236339B2 (en) 2016-06-17 2022-02-01 Ionis Pharmaceuticals, Inc. Modulation of GYS1 expression
CN109642224A (zh) 2016-06-22 2019-04-16 北卡罗莱纳州立大学 用于增加植物中的氮使用效率和/或氮利用效率的方法
EP3481430A4 (de) 2016-07-11 2020-04-01 Translate Bio Ma, Inc. Nukleinsäurekonjugate und verwendungen davon
MX2019000665A (es) 2016-07-15 2019-10-30 Basf Se Plantas que tienen una mayor tolerancia a herbicidas.
BR112019001483A2 (pt) 2016-07-27 2019-09-10 Basf Agro Bv método para controlar a vegetação indesejada em um local de cultivo de plantas
WO2018019842A1 (en) 2016-07-29 2018-02-01 Basf Se Method for controlling ppo resistant weeds
WO2018019845A1 (en) 2016-07-29 2018-02-01 Basf Se Method for controlling ppo resistant weeds
US20210352900A1 (en) 2016-08-05 2021-11-18 Basf Se Method for Controlling PPO Resistant Weeds
EP3278667A1 (de) 2016-08-05 2018-02-07 Basf Se Verfahren zur kontrolle von ppo-inhibitor resistenten unkräutern
WO2018024696A1 (en) 2016-08-05 2018-02-08 Basf Se Method for controlling ppo resistant weeds
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
NL2017295B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Antisense oligomeric compound for Pompe disease
EP3281523A1 (de) 2016-08-09 2018-02-14 Basf Se Verfahren zur bekämpfung von ppo-resistanten unkraut
EP3281524A1 (de) 2016-08-09 2018-02-14 Basf Se Verfahren zur bekämpfung von ppo-resistanten unkraut
WO2018029030A1 (en) 2016-08-09 2018-02-15 Basf Se Method for controlling ppo resistant weeds
EP3281525A1 (de) 2016-08-09 2018-02-14 Basf Se Verfahren zur bekämpfung von ppo-resistanten unkraut
US20190166841A1 (en) 2016-08-09 2019-06-06 Basf Se Method for Controlling PPO Resistant Weeds
WO2018029034A1 (en) 2016-08-09 2018-02-15 Vib Vzw Cellulose synthase inhibitors and mutant plants
BR112019001862B1 (pt) 2016-08-09 2022-10-18 Basf Se Métodos para controlar o crescimento de ervas daninhas resistentes a ppo, e uso do composto de fórmula (i).1
KR20190065341A (ko) 2016-10-06 2019-06-11 아이오니스 파마수티컬즈, 인코포레이티드 올리고머 화합물들의 접합 방법
WO2018067985A1 (en) 2016-10-07 2018-04-12 Altria Client Services Llc Composition and methods for producing tobacco plants and products having reduced tobacco-specific nitrosamines (tsnas)
CA3037046A1 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
JOP20190104A1 (ar) 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن atxn3
US11033570B2 (en) 2016-12-02 2021-06-15 Cold Spring Harbor Laboratory Modulation of Lnc05 expression
US11041166B2 (en) 2016-12-16 2021-06-22 Two Blades Foundation Late blight resistance genes and methods of use
MX2019007469A (es) 2016-12-20 2020-02-07 Basf Agro Bv Plantas que tienen una mayor tolerancia a herbicidas.
AU2017385601B2 (en) 2016-12-27 2022-08-25 Inbiose N.V. In vivo synthesis of sialylated compounds
WO2018140214A1 (en) 2017-01-24 2018-08-02 Pioneer Hi-Bred International, Inc. Nematicidal protein from pseudomonas
WO2018146481A1 (en) 2017-02-09 2018-08-16 Fujian Agriculture And Forestry University Expression of a phosphate transporter for improving plant yield
US11180756B2 (en) 2017-03-09 2021-11-23 Ionis Pharmaceuticals Morpholino modified oligomeric compounds
EP3612215A4 (de) 2017-04-20 2021-05-26 aTyr Pharma, Inc. Zusammensetzungen und verfahren zur behandlung von lungenentzündungen
EP3612232A1 (de) 2017-04-21 2020-02-26 The Broad Institute, Inc. Gezielte abgabe an beta-zellen
US11445692B2 (en) 2017-05-15 2022-09-20 Equi-Nom Ltd. Quantitative trait loci (QTL) associated with shatter resistant capsules in sesame and uses thereof
EP3658675A1 (de) 2017-07-28 2020-06-03 Two Blades Foundation Potyvirusresistenzgene und verfahren zur verwendung
US11197884B2 (en) 2017-08-18 2021-12-14 Ionis Pharmaceuticals, Inc. Modulation of the notch signaling pathway for treatment of respiratory disorders
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
EP3682011A1 (de) 2017-09-11 2020-07-22 Altria Client Services LLC Zusammensetzungen und verfahren zur herstellung von tabakpflanzen und -produkten mit verringerten oder beseitigten wurzeltrieben
TWI809004B (zh) 2017-11-09 2023-07-21 美商Ionis製藥公司 用於降低snca表現之化合物及方法
WO2019108619A1 (en) 2017-11-28 2019-06-06 Two Blades Foundation Methods and compositions for enhancing the disease resistance of plants
CR20200233A (es) 2017-11-29 2020-10-02 Basf Se Plantas que tienen una mayor tolerancia a herbicidas
EP3728574A1 (de) 2017-12-20 2020-10-28 Basf Se Nukleasen und verfahren zur herstellung und verwendung davon
WO2019126641A2 (en) 2017-12-21 2019-06-27 Ionis Pharmaceuticals, Inc. Modulation of frataxin expression
US11034969B2 (en) 2017-12-22 2021-06-15 Altria Client Services Llc Plant comprising recombinant polynucleotides encoding a pigment regulatory transcription factor with a tissue-preferred promoter
CN107868123B (zh) 2017-12-25 2020-05-12 中国农业科学院作物科学研究所 一种同时提高植物产量和抗性的基因及其应用
US11359208B2 (en) 2018-01-09 2022-06-14 Cibus Us Llc Shatterproof genes and mutations
CN111954464A (zh) 2018-01-12 2020-11-17 双刃基金会 秆锈病抗性基因及使用方法
TW201934129A (zh) 2018-01-15 2019-09-01 美商Ionis製藥公司 Ｄｎｍ２表現之調節劑
AU2019210093A1 (en) 2018-01-17 2020-07-09 Basf Se Plants having increased tolerance to herbicides
BR112020014242A2 (pt) 2018-02-14 2020-12-15 Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences Métodos de aumento da eficiência de uso de nutriente
WO2019169243A1 (en) 2018-03-02 2019-09-06 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-beta precursor protein
KR20200128064A (ko) 2018-03-02 2020-11-11 아이오니스 파마수티컬즈, 인코포레이티드 Irf4 발현의 조절제
EP3768694A4 (de) 2018-03-22 2021-12-29 Ionis Pharmaceuticals, Inc. Verfahren zur modulierung der fmr1-expression
US20210147847A1 (en) 2018-03-30 2021-05-20 Rheinische Friedrich-Wilhelms-Universitat Bonn Aptamers for targeted activaton of t cell-mediated immunity
US11377665B2 (en) 2018-04-03 2022-07-05 Altria Client Services Llc Composition and methods for producing tobacco plants and products having increased phenylalanine and reduced tobacco-specific nitrosamines (TSNAs)
CA3096274A1 (en) 2018-04-06 2019-10-10 Children's Medical Center Corporation Compositions and methods for somatic cell reprogramming and modulating imprinting
WO2019200172A1 (en) 2018-04-11 2019-10-17 Ionis Pharmaceuticals, Inc. Modulators of ezh2 expression
WO2019206994A1 (en) 2018-04-26 2019-10-31 Basf Se Lipase enzymes
US20210115422A1 (en) 2018-05-03 2021-04-22 Basf Se Amylase enzymes
US20210355497A1 (en) 2018-05-09 2021-11-18 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing fxi expression
CN112189053B (zh) 2018-05-09 2024-05-14 Ionis制药公司 用于减少atxn3表达的化合物和方法
WO2019219933A1 (en) 2018-05-17 2019-11-21 Vib Vzw An engineered combinatorial module of transcription factors to boost production of monoterpenoid indole alkaloids
CA3103429A1 (en) 2018-06-14 2019-12-19 Don W. Cleveland Compounds and methods for increasing stmn2 expression
EP3806619A1 (de) 2018-06-15 2021-04-21 Nunhems B.V. Kernlose wassermelonenpflanzen mit modifikationen in einem abc-transporter-gen
CA3104676A1 (en) 2018-06-27 2020-01-02 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing lrrk2 expression
US11690804B2 (en) 2018-07-02 2023-07-04 Aptamir Therapeutics, Inc. Targeted delivery of therapeutic agents to human adipocytes
EP3826645A4 (de) 2018-07-25 2023-05-17 Ionis Pharmaceuticals, Inc. Verbindungen und verfahren zur verringerung der atxn2-expression
CA3110661A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
AU2019334672A1 (en) 2018-09-07 2021-03-25 Basf Plant Science Company Gmbh Improved method for the production of high levels of PUFA in plants
CA3110651A1 (en) 2018-09-07 2020-03-12 Basf Plant Science Company Gmbh Improved method for the production of high levels of pufa in plants
CA3110656A1 (en) 2018-09-07 2020-03-12 Basf Plant Science Company Gmbh Improved method for the production of high levels of pufa in plants
CA3116477A1 (en) 2018-10-18 2020-04-23 Basf Se Method for the production of acrylic acid or salts thereof
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
AR117094A1 (es) 2018-11-15 2021-07-07 Ionis Pharmaceuticals Inc Moduladores de expresión irf5
EP3898987A1 (de) 2018-12-20 2021-10-27 Basf Plant Science Company GmbH Native verabreichung von biomolekülen in pflanzenzellen mittels ionischer komplexe mit zellpenetrierenden peptiden
BR112021014356A2 (pt) 2019-01-22 2021-10-05 Basf Se Nitrilase isolada, sequência de nitrilase isolada, processos de produção de ácido 4-cianobenzóico, construção recombinante, vetor recombinante, microrganismo recombinante, microrganismo, método de produção de uma nitrilase, composição e método de fabricação de uma solução aquosa
WO2020154466A1 (en) 2019-01-24 2020-07-30 Altria Client Services Llc Tobacco plants comprising reduced nicotine and reduced tobacco specific nitrosamines
SG11202107399WA (en) 2019-01-31 2021-08-30 Ionis Pharmaceuticals Inc Modulators of yap1 expression
GB201902253D0 (en) 2019-02-19 2019-04-03 Univ Court Univ Of Glasgow Methods for optogenetic manipulation of stomatal function
WO2020171889A1 (en) 2019-02-19 2020-08-27 University Of Rochester Blocking lipid accumulation or inflammation in thyroid eye disease
JP7492526B2 (ja) 2019-02-27 2024-05-29 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｍａｌａｔ１発現のモジュレーター
US20220186200A1 (en) 2019-03-11 2022-06-16 Basf Se Amylases and methods for making and using them
CA3133614A1 (en) 2019-03-14 2020-09-17 Rothamsted Research Limited Genetically modified plants with enhanced drought tolerance
WO2020193532A1 (en) 2019-03-25 2020-10-01 Basf Se Cleaning composition having amylase enzymes
EP3947665A2 (de) 2019-03-25 2022-02-09 Basf Se Amylaseenzyme
WO2020193534A2 (en) 2019-03-25 2020-10-01 Basf Se Amylase enzymes
EP3947684A4 (de) 2019-03-29 2023-09-20 Ionis Pharmaceuticals, Inc. Verbindungen und verfahren zur modulation von ube3a-ats
CN113825838A (zh) 2019-05-10 2021-12-21 巴斯夫欧洲公司 增强植物中基因表达的调节性核酸分子
US20220340918A1 (en) 2019-06-27 2022-10-27 Basf Plant Science Company Gmbh Methods for transformation of fungal spores
WO2020264237A1 (en) 2019-06-27 2020-12-30 Two Blades Foundation Engineered atrlp23 pattern recognition receptors and methods of use
US20210071193A1 (en) 2019-07-12 2021-03-11 The Regents Of The University Of California Plants with enhanced resistance to bacterial pathogens
US11786546B2 (en) 2019-07-26 2023-10-17 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating GFAP
CN114555621A (zh) 2019-08-15 2022-05-27 Ionis制药公司 键修饰的寡聚化合物及其用途
BR112022000573A2 (pt) 2019-08-22 2022-03-15 Basf Se Polipeptídeo isolado, sintético ou recombinante com atividade alfa-amilase, ácido nucleico isolado, sintético ou recombinante, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, método para produzir polipeptídeo isolado, sintético ou recombinante, método para preparar uma massa ou um produto de panificação, e, métodos para usar o polipeptídeo isolado, sintético ou recombinante e um domínio c de uma primeira amilase
EP4028530A1 (de) 2019-09-12 2022-07-20 Basf Se Regulatorische nukleinsäuremoleküle zur steigerung der genexpression bei pflanzen
WO2021058691A1 (en) 2019-09-26 2021-04-01 Basf Se Method for the production of beta-alanine or salts thereof
WO2021069387A1 (en) 2019-10-07 2021-04-15 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
US20230148071A1 (en) 2019-12-03 2023-05-11 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
US20230075913A1 (en) 2019-12-16 2023-03-09 BASF Agricultural Solutions Seed US LLC Codon-optimized cas9 endonuclease encoding polynucleotide
CA3161725A1 (en) 2019-12-16 2021-06-24 Timothy James Golds Precise introduction of dna or mutations into the genome of wheat
CN114829612A (zh) 2019-12-16 2022-07-29 巴斯夫农业种子解决方案美国有限责任公司 使用配对切口酶的改进的基因组编辑
CR20220485A (es) 2020-02-28 2022-11-10 Ionis Pharmaceuticals Inc Compuestos y métodos para modular smn2
KR20220149567A (ko) 2020-03-04 2022-11-08 바스프 에스이 이. 콜라이 및 바실루스에서의 발현을 위한 셔틀 벡터
WO2021175759A1 (en) 2020-03-04 2021-09-10 Basf Se Method for the production of constitutive bacterial promoters conferring low to medium expression
IL297435A (en) 2020-05-01 2022-12-01 Ionis Pharmaceuticals Inc Compounds and methods for modulating atxn1
BR112022022933A2 (pt) 2020-05-15 2022-12-20 Basf Se Quinase 1 isolada, processos de produção de fosfato de isopentenila, construções recombinantes, vetores recombinantes, microrganismos recombinantes, composições, processos de produção de pirofosfato de isopentenila, métodos para a produção fermentativa de um ou mais isoprenoides e para produzir um microrganismo recombinante, método de cultura ou crescimento, construção de expressão e processo para bioconversão
EP4172338A2 (de) 2020-06-29 2023-05-03 Ionis Pharmaceuticals, Inc. Verbindungen und verfahren zur modulierung von plp1
US11730133B2 (en) 2020-10-21 2023-08-22 Equi-Nom Ltd High yield sesame
TW202227101A (zh) 2020-11-18 2022-07-16 美商Ionis製藥公司 用於調節血管收縮素原表現之化合物及方法
CN117917951A (zh) 2021-05-11 2024-04-23 双刃基金会 用于抗病性功能测试的植物抗病基因文库的制备方法
TW202317765A (zh) 2021-06-18 2023-05-01 美商Ionis製藥公司 用於降低ｉｆｎａｒ１表現的化合物及方法
WO2023012342A1 (en) 2021-08-06 2023-02-09 Kws Vegetables B.V. Durable downy mildew resistance in spinach
WO2023031161A1 (en) 2021-09-03 2023-03-09 BASF Agricultural Solutions Seed US LLC Plants having increased tolerance to herbicides
US11395470B1 (en) 2021-09-14 2022-07-26 Equi-Nom Ltd. Sesame with high oil content and/or high yield
WO2023043220A1 (ko) 2021-09-16 2023-03-23 주식회사 큐마인 Wfdc2의 발현을 조절하는 안티센스 화합물
CA3233676A1 (en) 2021-09-30 2023-04-06 The Sainsbury Laboratory Plant disease resistance genes against stem rust and methods of use
WO2023067192A1 (en) 2021-10-21 2023-04-27 Consejo Superior De Investigaciones Cientificas (Csic) Methods for improving abiotic stress resistance
WO2023105244A1 (en) 2021-12-10 2023-06-15 Pig Improvement Company Uk Limited Editing tmprss2/4 for disease resistance in livestock
WO2023118136A1 (en) 2021-12-22 2023-06-29 BASF Agricultural Solutions Seed US LLC Improved screening method for genome edited events
WO2023131616A1 (en) 2022-01-05 2023-07-13 Vib Vzw Means and methods to increase abiotic stress tolerance in plants
WO2023131637A1 (en) 2022-01-06 2023-07-13 Vib Vzw Improved silage grasses
WO2023144199A1 (en) 2022-01-26 2023-08-03 Vib Vzw Plants having reduced levels of bitter taste metabolites
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024044352A1 (en) 2022-08-26 2024-02-29 The General Hospital Corporation Methods and compositions for prognosis and treatment of dilated cardiomyopathy and heart failure
WO2024083579A1 (en) 2022-10-20 2024-04-25 Basf Se Regulatory nucleic acid molecules for enhancing gene expression in plants
WO2024089011A1 (en) 2022-10-26 2024-05-02 BASF Agricultural Solutions Seed US LLC Excision of recombinant dna from the genome of plant cells
WO2024094678A2 (en) 2022-11-02 2024-05-10 Basf Se Improved method for the production of natural vanillin
WO2024098002A1 (en) 2022-11-04 2024-05-10 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
US20240173426A1 (en) 2022-11-14 2024-05-30 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503151A (en) * 1980-12-10 1985-03-05 Research Corporation Recombinant cDNA construction method and hybrid nucleotides useful in cloning
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4882279A (en) * 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
DE3788914T2 (de) * 1986-09-08 1994-08-25 Ajinomoto Kk Verbindungen zur Spaltung von RNS an eine spezifische Position, Oligomere, verwendet bei der Herstellung dieser Verbindungen und Ausgangsprodukte für die Synthese dieser Oligomere.
US4950599A (en) * 1987-01-29 1990-08-21 Wolf Bertling Method for exchanging homologous DNA sequences in a cell using polyoma encapsulated DNA fragments
WO1990014092A1 (en) * 1989-05-18 1990-11-29 Cell Genesys, Inc. Single-strand site-directed modification of mammalian genes in vivo
ATE244763T1 (de) * 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
WO1993022443A1 (en) * 1992-04-24 1993-11-11 Sri International In vivo homologous sequence targeting in eukaryotic cells
AU5087193A (en) * 1992-08-21 1994-03-15 Regents Of The University Of California, The Composition and method for altering dna sequences by homologous recombination
CA2159350A1 (en) * 1993-03-31 1994-10-13 Sudhir Agrawal Modified oligonucleotides having improved anti-influenza activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THOMAS M. DEVLIN, PH.D.: "Textbook of biochemistry with clinical correlations" , 1997, pages 596-599, WILEY-LISS, UNITED STATES OF AMERICA *

Also Published As

Publication number Publication date
AU691550B2 (en) 1998-05-21
CA2178729A1 (en) 1995-06-15
CN1048254C (zh) 2000-01-12
CN1117866C (zh) 2003-08-13
JP3585238B2 (ja) 2004-11-04
GR3034988T3 (en) 2001-03-30
US5871984A (en) 1999-02-16
ATE196311T1 (de) 2000-09-15
US5565350A (en) 1996-10-15
US5756325A (en) 1998-05-26
WO1995015972A1 (en) 1995-06-15
EP0733059A1 (de) 1996-09-25
KR100386337B1 (ko) 2004-03-24
DE69425903D1 (de) 2000-10-19
DE69425903T2 (de) 2001-02-15
EP0733059A4 (de) 1997-05-21
NZ278490A (en) 1998-03-25
CN1215755A (zh) 1999-05-05
JPH09506511A (ja) 1997-06-30
KR960706500A (ko) 1996-12-09
DE733059T1 (de) 1997-08-28
PT733059E (pt) 2001-03-30
AU1399595A (en) 1995-06-27
DK0733059T3 (da) 2000-10-16
ES2149962T3 (es) 2000-11-16
CN1142829A (zh) 1997-02-12

Similar Documents

Publication Publication Date Title
EP0733059B1 (de) Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
AU773242B2 (en) Genetic alteration in plants using single-stranded oligonucleotide vectors
US7053195B1 (en) Locked nucleic acid containing heteropolymers and related methods
US6852535B1 (en) Polymerase III-based expression of therapeutic RNAS
AU740702B2 (en) Cell-free chimeraplasty and eukaryotic use of heteroduplex mutational vectors
JPH08510388A (ja) 人工トランスポゾンのｉｎｖｉｔｒｏにおける転位
US20030148352A1 (en) Intracellular generation of single-stranded DNA
JP2014502161A (ja) オリゴヌクレオチドを用いたｄｎａの標的改変
AO et al. Antisense Inhibition of β-Glucuronidase Expression in Preimplantation Mouse Embryos: A Comparison of Transgenes and Oligodeoxynucleotides
KR20220039564A (ko) 신규의 개량된 염기 편집 또는 교정용 융합단백질 및 이의 용도
EP1533375B1 (de) Verfahren zur übertragung einer mutation in eine zielnukleinsäure
US20240052370A1 (en) Modulating cellular repair mechanisms for genomic editing

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960709

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: C12N 15/00

A4 Supplementary search report drawn up and despatched

Effective date: 19970407

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KMIEC, ERIC B.

EL Fr: translation of claims filed
TCNL Nl: translation of patent claims filed
DET De: translation of patent claims
17Q First examination report despatched

Effective date: 19970908

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

REF Corresponds to:

Ref document number: 196311

Country of ref document: AT

Date of ref document: 20000915

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REF Corresponds to:

Ref document number: 69425903

Country of ref document: DE

Date of ref document: 20001019

ITF It: translation for a ep patent filed

Owner name: SOCIETA' ITALIANA BREVETTI S.P.A.

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2149962

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20001211

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20031008

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20031016

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20031104

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20031201

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20031202

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20031219

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041209

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041231

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050609

EUG Se: european patent has lapsed
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Effective date: 20050609

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20051020

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20051025

Year of fee payment: 12

Ref country code: IE

Payment date: 20051025

Year of fee payment: 12

Ref country code: GR

Payment date: 20051025

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20051104

Year of fee payment: 12

Ref country code: BE

Payment date: 20051104

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20051107

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20051118

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20051130

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061231

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20061231

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070703

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20061209

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20070701

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20070831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061209

BERE Be: lapsed

Owner name: *THOMAS JEFFERSON UNIVERSITY

Effective date: 20061231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070102

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20061211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070102

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070704

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071209